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HsMCM8 AND HsMCM9: ESSENTIAL FOR DNA DOUBLE-STRAND BREAK REPAIR 
AND NORMAL OVARIAN FUNCTION 
Elizabeth Jeffries, PhD 
University of Pittsburgh, 2015 
The minichromosome maintenance (MCM) family of proteins is conserved from archaea 
to humans, and its members have roles in initiating DNA replication. MCM8 and MCM9 
are minimally characterized members of the eukaryotic MCM family that associate with one 
another and both contain conserved ATP binding and hydrolysis motifs. The MCM8-9 
complex participates in repair of DNA double-strand breaks by homologous recombination, and 
MCM8 is implicated in meiotic recombination. We identified a novel alternatively spliced 
isoform of HsMCM9 that results in a medium length protein product (MCM9M) that eliminates 
a C-terminal extension of the fully spliced product (MCM9L). Quantitative real-time reverse 
transcriptase PCR (qRT-PCR) of the relative mRNA isoform abundances across cell lines reveals 
MCM9L transcript is more abundant than MCM9M. The expression of both isoforms is cell 
cycle regulated, as they are most abundant in S-phase. Wild-type MCM9L forms DNA 
damage-dependent nuclear foci, while MCM9M is cytoplasmic and MCM9Cterm is diffuse 
throughout the nucleus. We have identified and verified a putative nuclear localization signal 
(NLS), and Rad51-interacting motif (BRCv) in the C-terminus of MCM9. GFP-tagged MCM9 
NLS- is solely cytoplasmic, GFP-tagged MCM9 BRCv- is diffuse throughout the nucleus. A 
combination of SNP arrays, comparative genomic hybridization arrays, and whole-exome 
v 
sequencing analyses identified homozygous pathogenic variants in MCM8 (MCM8 
c.446C>G; p.P149R) and MCM9 (MCM9 c.1732.2T>C and  MCM9 c.394C>T; p.R132*), all
located within regions of homozygosity in women afflicted by premature ovarian failure (POF). 
The MCM9 c.1732.2T>C variant alters a splice donor site, resulting in abnormal alternative 
splicing and truncated forms of MCM9 that are unable to be recruited to sites of DNA 
damage. In the second family, MCM9 c.394C>T (p.R132*) results in a predicted loss of 
functional MCM9. Compared with fibroblasts from unaffected family members, chromosomal 
break repair was deficient in fibroblasts from all affected individuals, likely due to inhibited 
recruitment of mutated MCM8 or MCM9 to sites of DNA damage. Our cumulative results 
suggest that MCM8-9 have evolved to act late in both mitotic recombination pathways to aid in 
crossover migration and/or strand resolution. 
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1.0  INTRODUCTION 
1.1 EUKARYOTIC DNA REPLICATION 
1.1.1 Eukaryotic DNA Replication and MCM Proteins 
DNA replication is an essential and delicately complex process in all living cells. It is vital to 
cellular survival and genomic stability that faithful genome duplication occurs exactly once per 
cell cycle in S phase (1-4). Aberrant DNA replication has been linked to several cancer types, and 
certain replication factors, when overabundant, have been identified as potential clinical 
biomarkers in cancerous tissues (2, 5-8). Through a variety of mechanisms, eukaryotic cells limit 
DNA replication to S phase (2). Both timing and location of DNA replication initiation are used 
as mechanisms of cell cycle control. Minichromosome Maintenance (MCM) proteins are known 
to play important roles in normal replication as well as homologous recombination for repair of 
double-strand DNA breaks. 
1.1.1.1 Replication Fork and Replication Origins 
Eukaryotic genomes are replicated from multiple origins of replication, located throughout the 
genome (9-11). The controlled recruitment and function of a diverse group of catalytically active 
proteins to multiple origins of replication is necessary to initiate faithful genome replication during 
S-phase (12). The assembly of these proteins, termed the pre-replication complex (pre-RC), is 
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complete upon recruitment of the hexameric MCM2-7 replicative helicase (12, 13) to chromatin; 
a process defined as the licensing of replication origins (14, 15). Activation of MCM2-7 as well 
as replication fork progression occur through the concerted action of Cdc45 and the protein 
complex GINS (16, 17). GINS is a complex named for the numbers 5-1-2-3 in Japanese (go-ichi-
ni-san), which refer to its four components, Sld5, Psf1, Psf2, and Psf3 (18, 19). The components 
of GINS were identified in a series of genetic screens in Saccharomyces cerevisiae, originally 
aiming to understand the function of Dpb11, a regulator of DNA polymerase ε (20). This screen 
led to isolation of several Sld (synthetic lethal with Dpb1-11) genes, including Sld5 (20). 
Subsequent genetic studies identified “Partners of Sld5”, or Psf proteins (21). The GINS complex 
has been shown to mediate interactions between MCM2-7 and other key factors (19). Following 
recruitment of the remaining members of the replisome, replication forks progress along double-
stranded DNA until they meet head-on, terminating replication (22).  
(a) Pre-Replication Complex 
The first member of the pre-RC to load onto chromatin is the origin recognition complex (ORC) 
(Fig. 1.1). Chromatin binding of ORC is followed by loading of replication factors Cdc6, Cdt1 and 
MCM2-7 (23) and is responsible for selecting genomic sites at which to begin replication (24). It 
is important that DNA replication initiation is coordinated with cell cycle progression and that the 
pre-RC is formed sequentially.  Each step of the pre-RC formation occurs only after completion 
of the previous step, and this ordered nature of pre-RC formation aids in the control of origin 
licensing (25). ORC is a six subunit protein complex that mediates the loading of MCM2-7 onto 
chromatin and the subsequent initiation of DNA replication (26, 27). The six subunits of ORC are 
AAA+ (ATPases Associated with a variety of Cellular Activities) ATPases and require ATP to 
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bind the genomic origin of replication (28). ORC facilitates recruitment of Cdt1-bound MCM2-7 
to chromatin by hydrolyzing ATP only when complexed to Cdc6.  
Figure 1.1 Pre-replication complex formation.  
Initial stages of pre-replication complex formation occur in G1 phase, when ORCs and Cdc6 bind to chromatin, 
recruiting Cdt1-bound MCM complexes. CDK and DDK regulate phosphorylation of MCM complexes, Cdc6 and 
Cdt1, which promotes dissociation of Cdt1 and Cdc6 from chromatin. The replication fork is established in S phase 
upon recruitment of Cdc45 and GINS, to complete the CMG complex. 
Cdc6 is a member of the pre-RC which also contains AAA+ ATPase motifs essential for 
proper DNA replication (Fig. 1.1) (29). The localization of the protein is cell cycle regulated in 
mammalian cells, being exported from the nucleus as a cell enters S phase (30). This regulation is 
likely to aid in prevention of unlicensed pre-RC formation. Cdc6 only associates with chromatin 
after ORC is bound and is required for MCM2-7 chromatin association (31, 32).
4 
Cdt1 was first identified in Schizosaccharomyces pombe as a gene necessary for 
replication. Cdt1 expression is regulated in a cell cycle dependent manner, peaking in G1 phase 
and decreasing in abundance as cells pass through S phase (33). Cdt1 has since been shown to be 
a necessary member of the pre-RC, associating with replication factor Cdc6 to cooperatively 
promote MCM2-7 association with chromatin (34). Cdt1 is conserved throughout eukaryotes and 
homologs have been identified in Xenopus laevis, humans and Drosophila melanogaster (4, 34, 
35). 
(i) Origin Licensing 
Cell-cycle coordinated control of pre-RC protein recruitment controls origin licensing. Pre-RC 
formation is regulated by two protein kinases, cyclin-dependent kinase (CDK) and Dbf4-
dependent kinase (DDK) (36). CDK may inhibit MCM loading onto chromatin by phosphorylating 
ORC, MCM and Cdc6 (37). CDK is also essential for helicase activation, phosphorylating the 
GINS components Sld2 and Sld3 to promote MCM loading onto chromatin. Both functions of 
CDK prevent recruitment of MCM2-7 to chromatin (38).  DDK promotes replication by 
phosphorylating MCM4 and MCM6. The activity of these kinases is cell cycle-regulated in order 
to temporally control the firing of replication origins (36).    
Geminin has a suggested role in controlling origin licensing by binding and directly 
inhibiting the function of Cdt1. Geminin abundance is regulated in a cell-cycle dependent manner, 
targeted for degradation during M phase by the anaphase-promoting complex (APC) (39). Geminin 
binds and stabilizes Cdt1 in G2/M phases of the cell cycle, blocking it from reinitiating origins of 
replication (40, 41). It has been suggested that the stoichiometry of the geminin-Cdt1 complex 
regulates DNA licensing (42, 43). Geminin accumulates on chromatin prior to genome duplication, 
following Cdt1 release from chromatin (44). The full-length isoform of the MCM9 protein has 
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been shown to form a stable complex with Cdt1 in Xenopus egg extract assays and this 
complexation is necessary for recruitment of the MCM2-7 complex to chromatin (41, 45).  
Figure 1.2 Minichromosome maintenance (MCM) protein family.  
Schematic shows alignment of conserved genetic motifs, including the zinc finger domain (Zn) and AAA+ core, 
containing the Walker A (WA), Walker B (WB) and Arginine finger (R) motifs. 
1.1.1.2 Minichromosome Maintenance (MCM) Proteins 
Minichromosome maintenance (MCM) proteins (Fig. 1.2) were discovered by randomly mutating 
a pool of samples of Saccharomyces cerevisiae and identifying mutants defective in the 
maintenance of plasmids (46). Mutations within the MCM genes result in a cell’s inability to 
replicate foreign plasmids. MCM2-9 are classified within the “pre-sensor 1 β-hairpin” (PS1βHP) 
subset of the AAA+ ATPase class of proteins. These proteins are characterized by a conserved 
core of amino acid motifs (29, 47). The basis of ATPase biochemical activity is an ability to 
hydrolyze the β-γ phosphate bond of a bound adenosine triphosphate molecule, releasing free 
energy (48, 49). AAA+ ATPases contain a conserved phosphate binding segment (“P-loop”) that 
interacts with the γ phosphate group of a bound ATP molecule (47, 50). Contained within the P-
6 
loop is the Walker A motif (GxxGxGKS), abbreviated “WA” in Fig. 1.2 (51). The Walker B motif 
(DExx, abbreviated “WB” in Fig. 1.2), also conserved among AAA+ ATPases is responsible for 
binding a Mg2+ cation, which facilitates ATP hydrolysis (48, 51). Sensor-1 (S1, Fig. 1.3) contains 
a conserved polar amino acid residue that senses ATP molecules, and mediates conformational 
changes in the enzyme in response to ATP (47, 50). In the active MCM2-7 hexameric helicase the 
conserved polar residue in Sensor-1 is positioned to allow for hydrogen bonding with the γ-
phosphate group of a bound ATP molecule (50). Sensor-2 (S2, Fig. 1.3), a conserved arginine 
residue also interacts specifically with the γ phosphate of a bound ATP molecule (47). An arginine 
finger (RF, Fig. 1.3) is contained within the AAA+ conserved sequence, and in hexamerized 
MCM2-7, protrudes from one member into the active site of another, inducing conformational 
changes necessary for ATP hydrolysis (47, 52). A zinc finger domain (ZF, Fig. 1.3) is contained 
in the N-terminus of all MCM family members, which serves a role in DNA binding. Also labeled 
in Fig. 1.3 are the winged helix (WH) domain and N-terminus to C-terminus linker domains, 
defined for their predicted structural roles based on their homology to motifs in SsoMCM 
(discussed in Chapter 3).  
Figure 1.3 Alignment of domains and motifs of MCM8 and MCM9 proteins.  
ZF: zinc finger domain; NHP: N-terminal Hairpin; N-C: N-terminal to C-terminal linker; WA: Walker A; WB: Walker 
B; S1: Sensor-1; RF: Arginine Finger; S2: Sensor-2 WH: winged-helix. 
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(a) MCM2-7 Replicative Helicase 
The MCM proteins that have been most extensively characterized are MCM2-7. The MCM2-7 
subunits interact with one another, forming a stable heterohexamer in solution. The MCM2-7 
hexamer functions as a replicative helicase, melting double-stranded DNA and allowing for 
subsequent elongation by a DNA polymerase (25, 53). Helicase activity of the heterohexamer was 
initially predicted on the basis of genetic motifs, and has been demonstrated in biochemical assays 
multiple times (13, 54-57). Biochemical assays have shown that an excess of chromatin-bound 
MCMs is necessary to allow a cell to withstand stress and further, not every MCM2-7 hexamer 
loaded on chromatin leads to a licensed replication origin (58). This finding raises a question 
regarding the function of these additional MCMC2-7 hexamers, termed the “MCM paradox.” The 
current prevailing interpretation is that these excess complexes license dormant origins to be used 
as a backup in the presence of replicative stress (58). 
The archaeal MCM proteins serve as simplified models for understanding the function and 
structure of eukaryotic MCM2-7.  The MCM homohexameric helicases found in 
Methanothermobacter thermoautotrophicus (Mth) and Sulfolobus solfataricus (Sso) have been 
studied to elucidate mechanisms of ATP hydrolysis, DNA binding and unwinding for this class of 
proteins (59). The AAA+ domain, located in the C-terminus of archaeal MCM proteins, contains 
conserved motifs essential for ATP hydrolysis, as a lysine residue mutation within this core 
abolishes unwinding activity (52). Mutational analyses of MthMCM have revealed essential motifs 
for DNA binding, including the N-terminal hairpin, presensor 1 hairpin and helix 2 insert (59).  
MCM hexamers possess a common architecture consisting of a central channel through 
which the DNA strand passes, an N-terminal domain which stabilizes the DNA and a C-terminal 
AAA+ ATPase domain (60-62). There is 3’-5’ polarity for MCM helicase unwinding, and residues 
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at the tips of the β-hairpins are critical for DNA binding and ATP hydrolysis in order to direct 
processivity (52, 63). The MCM hexamer contains two channels through which DNA may pass, 
the central channel and side channel. Three main models have been proposed for the mechanism 
of DNA unwinding by MCM hexamers. The proposed models are steric exclusion and wrapping 
(SEW) (64), steric exclusion and side channel extrusion (60). In the steric exclusion model, the 
double-stranded DNA is separated before entering the MCM central channel (65). The side 
channel extrusion model proposes that the MCM hexamer encircles both strands of DNA and 
strand separation occurs in the core of the MCM hexamer, then the displaced DNA strand is 
extruded through the side channel (61). Neither model proposes a role for the excluded or extruded 
strand. The SEW model of DNA unwinding proposes that the displaced DNA strand interacts with 
key residues on the exterior of the MCM hexamer, contributing to the activity of the helicase. In 
the development of the model, it was shown that the length of the 5’ tail impacts helicase 
processivity (64).  
While the archaeal MCM homohexamer serves as a simplified model by which to 
understand human MCM2-7, it is clear that the individual subunits of MCM2-7 are different but 
all essential for eukaryotic helicase activity (59). The three dimer interfaces in the heterohexamer 
form ATPase active sites, and mutational analysis reveals that these sites contribute unequally to 
the activity of the helicase, emphasizing the importance of all members of the heterohexamer (66). 
While a specific subset of MCM subunits (MCM467) is sufficient for in vitro helicase activity, 
this subset differs from MCM2-7 in its ability to bind circular DNA. Biochemical mutational 
analyses show that the MCM2/5 interface is necessary for MCM2-7 loading and activation (13). 
This interface forms a “gate” which opens to allow the hexamer to load onto circular ssDNA in 
vitro (13).  
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(b) MCM8 and MCM9 
MCM8 and MCM9 are present only in higher eukaryotes, and their functions remain poorly 
understood (67). These proteins form a stable nuclear complex, demonstrated by chromatin 
immunoprecipitation experiments (68). Despite its lack of a nuclear localization signal, MCM8 is 
localized to the nucleus throughout the cell cycle and bound to chromatin in S phase (69). Further, 
MCM8 mRNA accumulates in G1/S phase of the cell cycle, suggesting a role for the protein in 
DNA replication (69). Human MCM8 is implicated in pre-RC formation, as it interacts with the 
ATPase Cdc6, important for the licensing of origins of replication (70). Studies in Xenopus 
identified a role for MCM8 in the elongation step of DNA replication, but found the protein to be 
unnecessary for origin licensing (71). In contrast to these studies, experiments in Drosophila 
identified a role for MCM8 in meiosis but showed that the protein is not essential for DNA 
replication (72).  
The initial discovery of MCM9 from homology to expressed sequence tags (ESTs) 
identified a short isoform (MCM9S) of only 391 amino acids that lacks complete conservation of 
the AAA+ MCM core motifs (73). Full-length MCM9 protein was subsequently identified in 
Xenopus, and a homology search revealed the fully spliced human isoform (MCM9L), 1143 amino 
acids in length (67). It was shown that MCM9 shares highest total-amino acid identity with MCM8 
out of all MCM protein family members. Both MCM8 and MCM9 were initially implicated in 
DNA replication. Immunodepletion of XlMCM9 from egg extracts causes interruption of pre-RC 
formation resulting in inhibition of DNA replication (45). XlMCM9 binds chromatin in a manner 
dependent on ORC recruitment and forms a stable complex with Cdt1 presumably within the pre-
RC (45). Depletion of MCM8 in HeLa cells inhibits S-phase entry during normal replication, 
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suggesting a role for MCM8 in formation of the pre-RC (69, 70). MCM8 binds chromatin during 
S phase, following the formation of the replication fork (69).  
The necessity of MCM9 for pre-RC formation cannot be generalized to all vertebrates. 
Knockouts of MCM8 and MCM9 in mice have shown that neither MCM8 nor MCM9 are essential 
for DNA replication or organism survival but are needed for efficient homologous recombination 
(HR) as well as germ-line stem-cell maintenance and/or meiotic recombination (74, 75). Removal 
of MCM8 or MCM9 results in genomic instabilities, sex-specific tumor development, and sterility. 
MCM8 and MCM9 have been shown to interact directly and this complex is thought to participate 
in either preventing or repairing double strand breaks (74, 76). Both MCM8 and MCM9 are 
localized in cells as foci at DNA damage sites and are essential for the recruitment of other HR 
genes, including Rad51 (68). It is proposed that the MCM8-9 complex acts in some capacity as an 
ATP-dependent helicase to resolve complex DNA structures during HR. The contradiction 
regarding the necessity of MCM9 in eukaryotes could be explained by differences in Xenopous 
cell-free extract replication systems versus assays with whole cells or organisms. Alternatively, 
specific differences in alternative isoforms of MCM9 may provide differential or synergistic roles. 
Although it was initially thought that MCM9 was a vertebrate-specific protein due to its 
absence in Drosophila, nematodes, and yeast (67), it has now been identified in the genome of the 
invertebrate sea squirt (77) as well as many plants, parasites, and even fungi (78, 79) suggesting 
wider eukaryotic evolution (80). The collective findings suggest that MCM8 and MCM9 are a 
more recent evolutionary addition to the MCM family that is required for preventing or repairing 
DNA damage during replication that may lead to chromosomal instabilities and tumor 
development.  
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Comparative genomics and phylogenetic analysis been used to re-construct the 
evolutionary history of MCM2-9 (78). This analysis revealed that MCM2-7 are likely to have 
evolved from a single common ancestor, an archaeal-like MCM. MCM8 and MCM9 are 
widespread in eukaryotes, as they are present in five of the six eukaryotic supergroups (78). It is 
therefore likely that these proteins arose early in the eukaryotic evolution. MCM8 and MCM9 are 
co-present or co-absent in all organisms except Drosophila, suggesting co-evolution of the two 
(67). The co-absence or co-presence of MCM8 and MCM9 suggests related functions for the two 
proteins. MCM8 and MCM9 bear more sequence homology to one another than to any other MCM 
proteins, as shown by the dendrogram in Fig. 1.4, constructed using ClustalW, by comparing the 
Homo sapiens MCM amino acid sequences to one another. 
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Figure 1.4 Dendromer of HsMCM proteins.  
Dendromer was constructed using ClustalW, showing the high sequence homology between HsMCM8 and HsMCM9. 
In addition to the role established for MCM8-9 in repair of DNA DSBs, the protein 
complex is likely required for the resolution of double stranded DNA breaks that occur during 
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homologous recombination between homologous chromosomes in pachytene of meiosis I 
(discussed in 1.1.6) (72).  
Genome-wide association studies (GWAS) directed at identifying factors that determine 
reproductive lifespan have revealed single nucleotide polymorphisms (SNPs) in several genes, 
including MCM8, which are significantly involved in age of natural menopause (81). In addition 
to the sterility of MCM8 knockout mice, it has been established that homozygous mutations in 
MCM8 lead to primary amenorrhea in females and small testes and azoospermia in males (82). A 
nonsynonymous SNP in exon 9 of MCM8 (rs16991615), p.E341K, is highly associated with the 
age of natural menopause, and meta-analysis of menopause GWAS studies strongly implicates 
DNA repair pathways (81, 83-87). The functional relevance of p.E341K in reproductive 
senescence has not been elucidated. 
1.1.2 Repair of DNA Double-Strand Breaks 
DNA damage is an inevitable and potentially lethal threat to the genome of a cell. Lesions in the 
backbone of the cellular DNA may be caused by replication failure or by exogenous agents, such 
as ionizing radiation, ultraviolet light or chemical agents. Normal cellular functions also cause 
DNA lesions, specifically by production of reactive oxygen species as metabolic by-products. 
Double-strand breaks (DSBs), in which both strands of DNA are severed, are particularly 
detrimental to a cell. A single unrepaired DSB can result in cell death, (88) and misrepair of DSBs 
may lead to chromosomal rearrangements, causing genomic instability and cancer (89). Because 
of the significant threat posed by DSBs, cells have developed pathways for detecting and repairing 
DSBs in a timely, accurate manner. Two main pathways are available for the repair of DSBs: non-
homologous end joining (NHEJ) and homologous recombination (HR). HR requires large regions 
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of homology and is thus the prevalent repair pathway in S and G2 phases of the cell cycle, due to 
the availability of homologous donor sister chromatids during these phases.  
1.1.2.1 DNA-damage Checkpoints 
Regardless of the repair pathway used by a cell, all DSBs must first be sensed to allow for 
subsequent repair. Checkpoints are delays in cell cycle progress to allow for repair to take place. 
These checkpoints can signal delay or apoptosis and consist of phosphorylation cascades in which 
DNA-damage sensors detect unrepaired DSBs and recruit transducer kinases. In mammalian cells, 
the transducer kinases ATM (ataxia telangiectasia-mutated) and ATR (ataxia telangiectasia and 
Rad3-related) together with DNA-PKcs (DNA-dependent protein kinase catalytic subunit) play a 
central role in triggering activation of effector proteins, which repair the DNA damage (9). Several 
mediator proteins, including BRCA1 modulate the activity of the transducer kinases by 
interactions with members of the DNA damage response pathway (9, 90, 91). These checkpoint 
proteins direct DSB repair into one of two pathways (NHEJ or HR) dependent on the availability 
of a sister chromatid. 
1.1.3 Non-Homologous End Joining for Repair of DSBs 
In the absence of homology to a sister chromatid, NHEJ repairs DSBs by re-ligating the two broken 
ends together. As NHEJ does not require regions of homology, it is a more versatile and efficient 
DSB repair pathway than HR. However, the NHEJ pathway is rather error –prone as significant 
processing of the DSB ends is required before ligation. If DNA synthesis is necessary for gap 
filling, the accuracy of this pathway decreases dramatically (9). NHEJ is the primary repair 
mechanism in vertebrates due to the inefficiency of the homology search given the size and 
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repetitive nature of the genome (9). This is attributed to the inefficiency of the homology search 
given the size and repetitive nature of the genome. If the ends of the break contain overhangs, 
NHEJ may stabilize the ends of the DSB with base pairing. In order to facilitate this, terminal base 
degradation may be necessary. This degradation must not be extensive because NHEJ end joining 
is only efficient when overhangs consist of less than four bases (9, 92). It may be necessary for 
gaps to be filled in by DNA synthesis prior to ligation, although this step often results in insertions 
or deletions (93). The NHEJ pathway is inherently error prone and can lead to a variety of further 
genomic instabilities including chromosomal rearrangements.  
NHEJ is accomplished by three main protein complexes that function in structural 
stabilization as well as DNA degradation, polymerization and ligation. The three protein 
complexes are Ku (including DNA-dependent protein kinase, abbreviated DNA-PK), DNA ligase 
complexes and the MRN complex, composed of Mre11, Rad50 and Nbs1 (Fig. 1.5B-D). The MRN 
complex tethers the ends together, forming a bridge to structurally stabilize the DNA ends (Fig. 
1.5A). Ku and MRN are responsible for preventing degradation of the DSB ends by binding them 
shortly after formation of the DSB (Fig. 1.5 B). Ku and MRN also are involved in recruiting, 
stabilizing and stimulating the ligase complexes at the DSB (Fig. 1.5C) (9). If DNA end-
processing is necessary to facilitate ligation, Ku and MRN recruit DNA modifying factors to allow 
for this. The NHEJ process is dynamic, and until ligation occurs successfully, end-processing 
factors may continue to be recruited intermittently (9).  
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Figure 1.5 DNA Double-strand break repair by non-homologous end joining (NHEJ) or homologous recombination 
(HR) pathways (9).  
The initial step in both pathways is to tether the ends of the DSB by the MRN complex and Ku (specific to the NHEJ 
pathway) as well as DNA-PK complexes (A). (B) In the NHEJ pathway, the DSB ends are further stabilized by MRN 
and Ku/DNA-PK. (C) MRN and Ku/DNA-PK recruit DNA ligase and ends of the DSB are aligned. (D) DSB ends are 
ligated or are processed prior to ligation. (E) In the HR pathway, 5’ DSB ends are resected by MRN and other 
nucleases. (F) RPA binds to ssDNA ends remaining following resection. (G) RPA-coated ssDNA is a substrate for 
Rad51-filament formation. (H) Rad51-filament homology search and strand invasion produces the D-loop. (I) From 
the D-loop, different specific HR pathways can result in DSB repair.     
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1.1.4 Exogenous DNA Damaging Agents 
Cellular exposure to several exogenous agents is known to cause DNA double-strand breaks by a 
variety of mechanisms. Mitomycin C (MMC) is a potent DNA damaging agent that efficiently 
crosslinks DNA with specificity for CpG sites (94). While MMC was initially discovered as an 
antibacterial agent, its detrimental effects extend to mammalian cells as well. MMC causes 
mutagenesis and chromosome breakage in mammalian cells and has been used clinically as an 
antitumor agent (95). MMC operates by a mechanism in which it crosslinks the complementary 
strands of the DNA double helix, and is highly lethal to the cell (94). If left unrepaired, interstrand 
crosslinks are converted to DNA double-strand breaks during DNA replication (96). When the 
replication fork encounters these single-strand interruptions, the fork collapses, leading to double-
strand DNA ends.  
Exposure to ionizing radiation directly causes breaks in double-stranded DNA by breaking 
chemical bonds in the nucleotide structures (97). Often, free radicals are generated as by-products 
of the chemical bond breakage, and participate in further reactions to damage the molecular DNA 
structure. Exposure of a cell to camptothecin causes cytotoxicity by inhibiting the function of DNA 
topoisomerase I, preventing the enzyme from properly relaxing and reannealing newly replicated 
DNA strands (98).   
1.1.5 Homologous Recombination for Repair of DSBs 
HR is defined by three stages: presynapsis, synapsis and postsynapsis (99). The presynapsis stage 
of HR is identical to the beginning of NHEJ, and DSBs are detected by an interaction of the DNA 
ends with the MRN complex (100). Once the DSB is detected, a short 3’ ssDNA tail is created. 
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The BLM helicase acts to further resect the end of the DNA break, lengthening the 3’ overhang 
(Fig. 1.5E) (101). Following DNA resection, RPA, a single-stranded DNA binding protein is 
recruited to the overhang to stabilize and protect it (Fig. 1.5F). Mediator proteins, including 
Rad51B-Rad51C, Rad51D-XRCC, Rad52, and BRCA2, promote formation of a Rad51 filament 
(Fig. 1.5G). Rad51B-Rad51C, along with Rad51D-XRCC form a tetrameric complex that binds 
ssDNA, preserving it during the homology search (91).  Rad51C dimerizes with XRCC3, and this 
heteroproteincomplex functions to bind ssDNA and mediate recombination (91). Rad52 interacts 
with both Rad51 and RPA, and has ssDNA binding and annealing activity. BRCA2 interacts with 
Rad51, RPA and numerous other factors involved in the Fanconi anemia pathway, and also 
possesses ssDNA binding activity. Rad51 interacts with BRCA2 through 8 BRC repeat motifs, 
which are significantly conserved throughout mammalian BRCA2 (102, 103). Homologous 
motifs, classified as Rad51-interacting peptides (RIP) have been identified in RecQl5 (104). In 
addition to Rad51 association, there is evidence for these motifs playing a role in presynaptic 
filament stabilization (105, 106). RAD51 facilitates the search for a homologous segment on the 
sister chromatid, allowing for strand invasion, formation of the D-loop and homologous 
recombination (Fig. 1.5H) (91). Rad51 is not involved in the NHEJ pathway, but is unique to HR. 
BRCA1, a breast cancer susceptibility gene, associates and colocalizes with Rad51 (107). If 
BRCA1 or BRCA2 are depleted or mutated, a cell experiences genomic instability and cancer 
susceptibility (107). The synapsis stage consists of strand invasion, which forms a D-loop, and 
displacement of Rad51 to allow for DNA synthesis. The postsynapsis stage consists of branch 
migration and completion of repair by a crossover or noncrossover pathway (99). It has been 
demonstrated that MCM8 and MCM9 are important for recruitment of Rad51 to sites of DNA 
damage (68). 
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1.1.6 Poly(ADP-Ribose) Polymerases Detect DNA Strand Breaks 
Poly(ADP-ribose) polymerases (PARPs) are nuclear enzymes that detect and signal DNA strand 
breaks. While there are a total of 18 members of the PARP family of proteins, PARP-1 has been 
studied most extensively. PARP-1 efficiently binds DNA breaks through its N-terminal zinc finger 
and recruits DNA repair proteins to the site of damage (108-110) (Fig. 1.6). Upon binding, a post-
translational modification occurs on histones H1 and H2B, causing chromatin to relax and DNA 
to become more accessible (111). PARP-1 undergoes a conformational change and uses NAD+ as 
a substrate for synthesis of poly(ADP-ribose) (PAR) oligomers. PAR is responsible for modifying 
chromatin architecture and recruiting proteins for further chromatin modification as well as 
recruiting SSB repair enzymes. PARP-1 catalyzes the synthesis of PAR using NAD+ as a 
substrate. PAR serves two main roles in response to DNA strand breaks: relaxing chromatin to 
increase accessibility of DNA and recruiting DNA repair proteins (111, 112). Addition of PAR 
oligomers usually leads to successful and efficient repair of DNA damage, but in cases of extreme 
damage may induce apoptosis (113).  
Figure 1.6 Function of PAR in DNA DSB detection and signaling.  
After introduction of a DSB by agents such as MMC, camptothecin or ionizing radiation, PARP-1 and PARP-2 bind 
to the site of damage and poly (ADP-ribose) oligomers are produced on the surface of PARP-1 and PARP-2, which 
function both in relaxing chromatin to spatially accommodate repair factors and to recruit XRCC1 to the site of 
damage.  
When PARP-1 is inhibited, single-strand breaks collapse replication forks and homologous 
recombination is triggered to repair the DNA break (114, 115). Because of the initiation of HR in 
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the absence of functional PARP-1, cells deficient in HR proteins are acutely sensitive to PARP 
inhibitors. This heightened susceptibility has been demonstrated in BRCA2-deficient tumor cells 
(115), PTEN-deficient tumor cells (116) and PTEN-mutated cells (117). Because of the high 
dependence of PARP-inhibited cells on HR, many forms of cancer are more dependent on PARP 
than are healthy cells. Inhibitors of PARP have been shown to be effective in tumor suppression 
as they enhance the effects of ionizing radiation and DNA-damaging chemotherapy agents. 
Currently, several PARP inhibitors are being developed and implemented for clinical treatment of 
cancer (118, 119).   
1.1.7 Meiotic Recombination 
Meiosis is a type of cell division by which an organism halves its chromosome number in order to 
maintain its genomic size in each generation. The process consists of a single round of DNA 
replication followed by two rounds of chromosome segregation. Most cells contain two copies of 
each chromosome, but for sexual reproduction these two copies must separate from one another to 
produce sperm or eggs with one copy of each chromosome. Homologous recombination plays a 
role in this segregation of chromosomes as it allows for physical connections between chromosome 
pairs to create genetic diversity. Only physically connected chromosomes will orient properly on 
the meiotic spindle (120). A role for MCM8-9 in meiotic recombination has been proposed (72), 
which supports the role of the protein complex in homologous recombination.  
Studies in Saccharomyces cerevisiae reveal fundamental similarities between double-
strand break repair and meiotic recombination (121). While the purposes of these two pathways 
differ, the underlying mechanisms share many protein factors in common, including Rad51 and 
BRCA2 (122). The commonality of Rad51 in particular suggests a role for MCM8-9 in meiosis, 
21 
given the established role of the complex in HR for double-strand break repair, even though 
MCM8-9 are absent in Saccharomyces cerevisiae. A comparison of the purpose, timing and 
outcomes of meiotic recombination and HR for repair of double-strand breaks is shown in  
Fig. 1.7.  
Figure 1.7 Comparison of the purposes, causes and outcomes of meiotic recombination and HR for double-strand 
break repair.  
These processes respectively result in crossover (CO) or non-crossover (NCO) products. 
Rad51 and BRCA2 are common to HR for DSB repair and meiotic recombination. Rad51 
along with Dmc1, a protein factor unique to meiotic recombination, carry out the homology search 
in meiotic recombination (122). BRCA2 is important for single strand invasion in Arabidopsis 
thaliana, in meiotic recombination. As discussed above, the MCM8-9 complex colocalizes with 
Rad51 to sites of DNA damage and is essential for Rad51 recruitment to damage sites. Given the 
importance of MCM8-9 in repairing DSBs by HR, the MCM8-9 complex is likely involve in the 
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resolution of double stranded DNA breaks that occur between homologous chromosomes in 
pachytene of meiosis I. While MCM9 is absent from Drosophila, MCM8 has been shown to be 
essential for 95% of Drosophila melanogaster meiotic crossovers (72). In light of this role of 
MCM8, the effect on meiosis of mutations in Arabidopsis thaliana MCM8 was investigated. 
Interestingly, the introduction of these mutations in MCM8 lead to chromosome fragmentation 
after the formation of meiotic DSBs, suggesting a role for MCM8 in the repair of DSBs (123). In 
the absence of Dmc1, mutated MCM8 produces even more chromosome fragmentation. 
Chromosomal crossover remains uninhibited in the absence of functional MCM8, however, but 
does not occur in the absence of Dmc1. These findings established a role for MCM8 in resolution 
of Drosophila meiotic DSBs, but not chromosomal crossover. It is suggested that MCM8 and 
Rad51 act in parallel with Dmc1, resolving DSBs, but are unable to produce crossovers when 
Dmc1 is absent (123). 
Studies in MCM8- and MCM9-null mice directly reveal a role for MCM8 and MCM9 in 
meiosis (74). While mouse knockout models of MCM8 and MCM9 are viable, all except   MCM9-
/- males are sterile (74). In MCM8-/- males, spermatocytes have persistent DNA damage and are 
defective in HR, exemplified by their unsynapsed chromosomes. MCM8-/- ovaries exhibit a block 
in follicle development as well as tumor development. MCM9-/- ovaries lack oocytes and testes 
exhibit a proliferation defect of germ cells. Further, MCM8- and MCM9-null mouse embryonic 
fibroblasts exhibit growth defects, chromosomal damage and heightened sensitivity to replication 
fork stress. Knockout MEFs are also defective in HR-mediated repair of DNA breaks, including 
an inability to recruit HR factors Mre11, RPA, and Rad51 (74).  
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1.2 GENE TRANSCRIPTION AND RNA SPLICING 
Eukaryotic genes are discontinuous, consisting of coding exons separated by noncoding intronic 
regions (124). When eukaryotic genes are transcribed into precursor mRNA (pre-mRNA), 
particular exons may be included or excluded, allowing for production of multiple alternatively 
spliced pre-mRNA isoforms from a single gene. Alternative splicing is a regulated process during 
transcription that results in a single gene coding for multiple proteins. This is a means of 
significantly increasing the diversity of proteins synthesized from limited genomic information 
(125). The control of splicing is an essential aspect of eukaryotic gene regulation, as it is only 
through alternative splicing that an organism is able to produce the diversity of proteins necessary 
for the accomplishment of the various functions it requires (126). Alternative splicing is 
widespread throughout eukaryotes, with 100% of human genes producing more than one 
alternative mRNA isoform and an average of three alternatively spliced transcripts produced by 
each human gene (125).  
There are multiple modes of alternative splicing, and exon skipping, in which a single exon 
is alternatively excluded or included in a transcript, is the most common (127). In addition to exon 
skipping, exons may be mutually excluded to produce alternative pre-mRNA isoforms. In this 
mode, mRNAs include one of several exons, but no more (127). Alternative donor (5’ junction) 
sites and acceptor (3’ junction) sites may also be used to produce multiple mRNA transcripts from 
a single gene (128, 129). Alternatively spliced transcripts may arise from inclusion of intronic 
regions, which code for amino acids in these cases(129). All modes of alternative splicing can 
cause a frame shift in the resulting protein, which can lead to a premature stop codon and loss of 
protein function.      
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1.3 PREMATURE OVARIAN FAILURE 
1.3.1 Clinical Diagnosis and Known Causes 
Premature ovarian failure (POF) affects 1-4% of women, and is defined as a cessation of menses 
prior to age 40, with elevated follicle stimulating hormone (FSH) and low serum estradiol levels 
(130). Women with POF present with amenorrhea (primary or secondary), and hypoestrogenic 
symptoms. POF is genetically heterogeneous (131), with few genes identified, and can be 
idiopathic and non-syndromic or part of a genetic syndrome. While hereditary factors have been 
identified in POF, genetic causes are still being investigated. 
In 90% of POF cases, the cause is unknown. There are a few causative genetic factors that 
have been identified. Single genes, such as bone morphogenetic protein 15 [BMP15], diaphanous 
homolog 2 [DIAPH2], and inhibin alpha subunit [INHA] have been associated with POF and 
structural abnormalities in the X chromosome may also cause POF (130). Many of the genes 
associated with POF are involved in repair of DNA breaks by homologous recombination, 
suggesting that mutations in HR genes increase the likelihood of developing POF. Efforts are being 
made to define genetic biomarkers of ovarian reserve which may serve as a prediction of ovarian 
function. Genome-wide association studies have identified approximately 20 genomic loci which 
correlate with POF, but no single cause has been identified (131).  
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2.0  IDENTIFICATION, QUANTIFICATION, AND EVOLUTIONARY ANALYSIS 
OF A NOVEL ISOFORM OF MCM91 
2.1 IDENTIFICATION OF A NOVEL ISOFORM OF MCM9 
2.1.1 Research Design 
We have identified a novel mRNA isoform of HsMCM9 resulting from an alternative splicing 
event in precursor mRNA (pre-mRNA) producing a medium isoform (MCM9M) more consistent 
with the amino acid size of the rest of the MCM family members. Full length MCM9L contains 12 
contiguous exons, while in MCM9M, exon 11 is excluded. This exclusion results in a frame shift 
from exon 10 to 12, causing a premature stop codon and truncation of the unconserved C-terminal 
extension. For the first time, we have separately quantified the individual mRNA expression levels 
of the two functional AAA+ MCM9 isoforms (MCM9L and MCM9M) in a panel of human cell 
lines. The expression profiles of both MCM9 isoforms are cell cycle regulated, peaking during S-
phase and returning to basal levels as the cell cycle progresses through G2/M and into G1. The 
cell cycle profile of MCM9 differs slightly between the two isoforms examined and significant 
differences are noted in early S-phase and G2/M. Induction of DNA crosslinks using mitomycin 
C leading to double strand breaks causes MCM9L specifically to be transcriptionally activated, 
whereas stalled replication forks from hydroxyurea treatment had no effect on MCM9 
1 This section is taken from “Jeffries EP, Denq WI, Bartko JC & Trakselis MA (2013). 
Identification, quantification, and evolutionary analysis of a novel isoform of MCM9. Gene 
519, 41-49.” Permission to reprint was obtained from Elsevier Journals. 
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transcription. These results identify, characterize, and validate a novel MCM9M isoform that lacks 
the long C-terminal extension placing it more consistent in length with the rest of the MCM family 
as well as medium length MCM9 variants in a variety of other eukaryotes. The cumulative 
expression data suggests that MCM9M and MCM9L may have different regulated roles for DNA 
maintenance.   
2.1.2 Results and Discussion 
2.1.2.1 Identification of a Novel Human MCM9 Isoform 
Because MCM9 has previously been shown to exist in two isoforms (MCM9S and MCM9L), we 
investigated the possibility that other isoforms may also exist. By amplifying short 
Figure 2.1 Identification of MCM9M (A) PCR amplification products of (B) short overlapping segments of the first 
10 exons from HeLa cDNA, all producing a single product band.  
Forward and reverse primers were designed to amplify a 737-bp region spanning exons 1-4, a 435-bp region spanning 
exons 3-6 and an 858-bp region spanning exons 5-10. (C) Detection of MCM9M and MCM9L splice variants using 
E9Fb forward and E12R reverse primers giving 285 and 481 bp products, respectively. DNA sequencing results of 
(D) MCM9L shows the junction of exons 10 and 11 and (E) MCM9M shows the junction of exons 10 and 12, skipping 
exon 11.  
regions of MCM9 cDNA spanning multiple exons, we identified a unique mRNA isoform of 
HsMCM9 that results from an alternative splicing event (Fig. 2.1). Amplification of the 
overlapping regions spanning exons 1-4, 3-6, and 5-10 all resulted in a single predicted product 
band, indicating that contiguous splicing occurs within exons 1-10 of HsMCM9 (Fig. 2.1A-B). 
However, amplification of the region spanning exons 9-12 produced two distinctly sized DNA 
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products from a single primer pair (E9Fb and E12R). DNA sequencing revealed that the longest 
fragment (431 bp) contains a fully spliced product, while the shorter fragment (285 bp) lacked all 
146 base pairs of exon 11 (Fig. 2.1 C-E).  
In addition to the two previously identified isoforms of MCM9 (MCM9S and MCM9L) (73, 
132), we have detected a third isoform (MCM9M) that is the result of an alternative splicing event 
that effectively removes exon 11. Exons 10 and 12 are directly spliced, shifting the reading frame 
and resulting in a premature nonsense stop codon within exon 12 after translation of 43 unique 
amino acids at the C-terminal end. This is predicted to produce an isoform that eliminates the 
uncharacteristic C-terminal extension of MCM9L and is more consistent in size with the rest of the 
MCM family members (Fig. 2.2). Splicing of MCM9M is fundamentally different than MCM9S, 
where the intron following exon 6 is retained and becomes part of the mRNA reading frame. 
Figure 2.2 Alternative splicing of MCM9.  
(A) Alternatively spliced MCM9 pre-mRNAs give rise to (B) multiple predicted protein products. HsMCM9M, 
outlined by the dashed red line, is the newly discovered isoform of MCM9. 
2.1.2.2 Separation and Quantification of Expression Levels of MCM9M and MCM9L 
We optimized the DNA primers to allow for specific amplification of short but similarly sized 
segments of MCM9SML (270 bp), MCM9L (275 bp) and MCM9M (261 bp) (Fig. 2.3A, C-D). 
Primers E3F and E5R anneal specifically to the region universally conserved among all MCM9 
28 
isoforms, producing a single PCR product (Fig. 2.3B).  For specific amplification of MCM9M and 
MCM9L, a common forward primer (E9Fa) is paired with unique regions in the two isoforms: exon 
11 in MCM9L (E11R) or the region overlapping exons 10 and 12 in MCM9M (E11SkipR). The 
two reverse primers were designed to have similar melting temperatures, and E11SkipR was 
optimized with regard to the number of bases annealed to either exon 10 or 12 (from 8-16 bases in 
exon 10 and 6-11 bases in exon 12). To show specificity, each cDNA isoform (MCM9M or 
MCM9L) was cloned into pGEMT, and PCR was performed with each possible forward and 
reverse primer pair giving only the appropriately sized products without any significant 
background (Fig. 2.3E). Total RNA was isolated from cultures of five cancer cell lines: HeLa, 
MDA-MB-231, MCF-7, PCI-13 and A549 as well as normal skin keratinocytes (HaCaT). Both 
MCM9M and MCM9L were specifically detected from cDNA from each of these cell lines in semi-
quantitative RT-PCR reactions (Fig. 2.3F).  
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Figure 2.3 Separate quantification of MCM9L, MCM9M and MCM9SML. 
Sites of specific RT-PCR primer annealing for (A) MCM9SML, (C) MCM9L and (D) MCM9M resulting in 270 bp, 275 
bp and 261 bp products, respectively. (B) Specific PCR amplification of MCM9SML from a control plasmid containing 
MCM9L. (E) Specificity of PCR amplification of MCM9 splice variants from control plasmids containing each MCM9 
isoform. Lane 1: pGEMT-MCM9L with E9Fa and E11SkipR. Lane 2: pGEMT-MCM9M amplified with E9Fa and 
E11SkipR. Lane 3: pGEMT-MCM9L amplified with E9Fa and E11R. Lane 4: pGEMT-MCM9M with E9Fa and E11R. 
(F) Two primer sets (E9Fa/E11SkipR for MCM9M or E9Fa/E10R for MCM9L) were used to specifically amplify each 
isoform of MCM9 from cDNA isolated from human cancer cells (HeLa, A549, PCI-13, MDA-MB231, and MCF-7) 
as well as normal skin keratinocytes (HaCaT) in semiquantitative RT-PCR experiments. (G) The three primer sets 
shown in (A), (C) and (D) were used to amplify MCM9SML, MCM9L and MCM9M by qRT-PCR from HeLa cDNA, 
respectively. 
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 To more accurately quantify the relative amounts of each mature MCM9 mRNA isoform 
(MCM9M or MCM9L) compared with the sum of all isoforms (MCM9SML), we used quantitative 
real-time reverse transcriptase PCR (qRT-PCR). To provide a standard data set and for 
quantification of relative expression levels, DNA primers were also designed to amplify a 188 bp 
region of the housekeeping gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase) (133). 
GAPDH cycle threshold (CT) values were subtracted from HsMCM9 CT values obtained from a 
single HeLa RNA template and the resulting ∆CT values are reported in Fig. 2.3G and Table 2.1. 
For each averaged ∆CT data point, the error bars are the standard deviation of the mean of at least 
three independent experiments each performed in triplicate. The level of expression of MCM9SML 
in HeLa cells is consistent with the expression profile data compiled by the European 
Bioinformatics Institute which quantifies total MCM9 (sum of all isoforms) at least 9 logs lower 
than GAPDH and 6 logs lower than MCM2 in a variety of cell and tissue types (134).  
Table 2.1: qRT-PCR CT values normalized to GAPDH CT values, reported as ΔCT.
ΔCT1 
Cell Line MCM9L MCM9M MCM9SML
N. Cervix2 12.0 ± 1.1 15.0 ± 1.1 ND3 
A549 17.6 ± 0.6 23.9 ± 0.8 ND3 
HeLa 21.2 ± 0.9 22.2 ± 0.6 11.0 ± 1.3 
MDA-MB-231 23.0 ± 0.5 24.3 ± 0.5 ND3 
PCI-13 16.2 ± 0.7 23.1 ± 1.4 ND3 
MCF-7 21.7 ± 1.2 26.3 ± 0.8 ND3 
1Averages taken from at least three independent 
experiments performed in triplicate. 2Normal cervix RNA was 
purchased. RNA from all other cells lines was isolated from 
cells grown in culture. 3ND- not determined.
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Importantly, the ΔCT values for MCM9SML (targeting common exons 3-5) are roughly 10 
logs less than for either MCM9M or MCM9L alone highlighting that multiple isoforms exist and 
can be quantified either simultaneously or independently with drastically different results. 
Figure 2.4: MCM9L or MCM9M abundances in cancer cell lines.  
qRT-PCR experimental results from total RNA extracted from indicated human cell lines. GAPDH CT values were 
subtracted from MCM9 CT values giving reported ∆CT. Statistical significance (p-values) was evaluated for each pair 
of MCM9 isoforms, MCM9L (black) or MCM9M (grey), in each cell line (* = p < 0.05; ** = p < 0.01). At least three 
individual experiments performed in triplicate were used to calculate the standard deviation. 
Further, we individually quantified MCM9M and MCM9L mRNA levels in each of the 
above cell lines as well as a commercial normal cervical RNA sample using qRT-PCR (Fig. 2.4). 
For each RNA template, a p-value was calculated to determine the statistical significance of the 
difference between the ∆CT values of the two MCM9 isoforms (* = p < 0.05; ** = p < 0.01). Both 
isoforms are in low abundance compared with GAPDH reflected in the positive ∆CT values, but 
interestingly, the abundance of MCM9L is greater than MCM9M in every cell line tested. 
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Statistically significant differences between MCM9L and MCM9M expression levels were detected 
at the p < 0.05 (normal cervix and MCF-7) and p < 0.01 (A549 and PCI-13) levels and can be seen 
when directly compared using a 2−∆∆𝐶𝐶𝑇𝑇 plot (Fig. 2.5). All relative abundances represented in Fig. 
2.5 represent experiments performed in triplicate. In those RNA templates with significant 
differences, we found MCM9L to be more abundant by 2-7 logs over MCM9M. The two breast 
cancer cell lines (MCF-7 and MDA-MB231) exhibit the lowest abundances of MCM9L and 
MCM9M. Expression levels of MCM9 isoforms from commercial normal cervix RNA are 
significantly greater than any of the other cell lines, but these absolute values should be interpreted 
with caution as the cells were not grown under the same conditions. qRT-PCR was also attempted 
on HaCaT RNA without consistently reliable results above threshold values, suggesting even 
lower expression levels in these cells.  
Figure 2.5 Relative cancer cell line abundances of MCM9L and MCM9M. 
MCM9M ΔCT values were subtracted from MCM9L ΔCT values, as shown in Figure 4 and Table 1, to yield ΔΔCT 
values for each cell line. At least three individual experiments performed in triplicate were used to calculate the 
standard deviations. 
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Quantification of the mRNA transcripts shows that MCM9M is ubiquitously present at a 
concentration equal to or significantly lower than MCM9L in a variety of cell types.  
2.1.2.3 MCM9 Isoforms are most abundant in S-phase 
Figure 2.6 FACS cell cycle profiles of double thymidine synchronized HeLa cells.  
Profiles are of synchronized HeLa cells collected at individual time points after release from double thymidine, stained 
with propidium iodide (PI) at the following time points: (A) 1 Hr, (B) 2 Hr, (C) 11 Hr, (D) 18 Hr, and (E) asynchronous. 
The relative populations of cells in each cell cycle phase (S, G2/M, or G1) gated from the asynchronous population 
are quantified.  A total of 10,000 cells were analyzed for each timepoint. 
To investigate the cell cycle expression profile of either MCM9 isoform, we synchronized HeLa 
cells at the beginning of S-phase using a double thymidine block and at the G2-M boundary using 
nocodazole. RNA was isolated at various time points following release covering the entire cell 
cycle. The HeLa cell line was chosen for synchronization because of the similarity between 
MCM9M and MCM9L expression levels in asynchronous cells. Fluorescence activated cell sorting 
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(FACS) was used to verify the cell cycle phases of the points after release from synchronization 
(Fig. 2.6 and 2.7). Release from nocodazole and progress through G1 is slightly longer than normal 
presumably due to incomplete or slow removal of nocodazole but progressed into S-phase 
normally and synchronously.  
Figure 2.7 FACS cell cycle profiles of nocodazole synchronized HeLa cells. 
Profiles are of individual time points after release from nocodazole synchronized HeLa cells, stained with propidium 
iodide (PI) at the following time points: (A) 4 Hr, (B) 8 Hr, (C) 12 Hr, (D) 16 Hr, and (E) asynchronous. The relative 
populations of cells in each cell cycle phase (S, G2/M, or G1) gated from the asynchronous population are quantified.  
A total of 20,000 cells were analyzed for each timepoint. 
qRT-PCR experiments were performed as described above for each MCM9 isoform on the 
isolated RNA from the synchronized time points corresponding to each phase of the cell cycle. 
Fig. 2.8 and Table 2.2 show the ∆CT values for the two MCM9 splice variants relative to GAPDH 
across the cell cycle. Statistical significance of transcript abundances are indicated by p-values (* 
= p < 0.05). Consistent with the relative isoform abundance observed in asynchronous cells, 
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MCM9L is more abundant than MCM9M at all points in the cell cycle. Strikingly, both MCM9M 
and MCM9L are induced significantly during S-phase before decreasing to basal levels during G2 
and into M-phase. However, the trends in expression levels of the two isoforms are not exactly 
identical. The magnitude of the expression level change is greater for MCM9L than MCM9M at the 
start of S-phase. The decreases in expression levels of MCM9L and MCM9M after S-phase are 
significantly different compared points in G1 highlighting true changes in transcription after DNA 
replication has begun. This, along with the lower abundance of MCM9M in all RNA samples, 
suggests that there are significant differences in the transcriptional regulation of MCM9M and 
MCM9L.  
Figure 2.8 Comparison of the abundances of MCM9L and MCM9M, assessed by qRT-PCR. 
Assay was performed using total RNA extracted from time points after release of cell cycle synchronized HeLa cells. 
The FACS profiles for each time point is shown in Supplemental Figure S1. GAPDH CT values were subtracted from 
those for MCM9 isoforms at each time point and reported as ΔCT (also in Table 2). At least three individual 
experiments performed in triplicate were used to calculate the standard deviations. Time = 0 on the x-axis corresponds 
to final release from nocodazole (* = p < 0.05). 
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Table 2.2: qRT-PCR ΔCT values for synchronized HeLa cells normalized to GAPDH CT values. 
Expression of MCM9 is induced both in S-phase and after exposure to DNA damaging 
conditions, validating its importance in DNA maintenance activities. The exact role or roles of the 
MCM9 isoforms in the cell are currently unknown, but significant differences in expression levels 
between MCM9M and MCM9L in some cell types and at certain stages of the cell cycle may 
indicate that they are individually regulated or utilized. Interestingly, both breast cancer cell lines, 
MDA-MB231 and MCF-7, have the lowest abundance of both MCM9 isoforms compared to all 
other cell lines tested. The variations in expression levels between MCM9M and MCM9L across 
cell types do not correlate with cytogenetic data for chromosome 6. Therefore, transcriptional 
levels are regulated directly by specific elements for each cell type.  
Our cell cycle results are also consistent with a previous expression profile specifically 
targeting MCM9S from mouse fibroblasts using semi-quantitative RT-PCR that detected 
transcriptional induction in S-phase after release from G0 (73). The similarity between our results 
Cell Cycle 
Phase 
ΔCT2
SSync MCM9L MCM9M
DDT1 Mid S 13.6 +/- 0.9 16.4 +/- 0.7 
Late S 18.0 +/- 0.7 20.4 +/- 0.5 
M 17.1 +/- 1.2 24.0 +/- 1.0 
Late G1 19.3 +/- 0.6 23.0 +/- 0.4 
NN3 Early G1 20.0 +/- 0.8 22.8 +/- 2.2 
Mid G1 19.9 +/- 0.6 21.9 +/- 0.1 
Late G1 21.8 +/- 1.0 22.3 +/- 1.1 
Start S 23.2 +/- 0.6 23.1 +/- 1.8 
Asynchronous 21.2 +/- 0.9 22.2 +/- 0.6 
1DT – double thymidine synchronization. 2Averages 
taken from at least three independent experiments 
performed in triplicate. 3N – nocodazole 
synchronization 
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for MCM9M and MCM9L and those for MCM9S would suggest that both transcriptional activation 
and pre-mRNA transcript processing are important for function during S-phase. It is possible that 
the large induction of MCM9 expression relative to GAPDH in S-phase is a consequence of halting 
the cell cycle with thymidine for synchronization (135), but this protocol has been used routinely 
to synchronize cells and assess changes in expression for a variety of transcripts and proteins. 
Normalization to GAPDH as ΔCT values also minimizes any global expression differences due to 
synchronization. There are also significant differences in the cell cycle expression profile for 
MCM9M compared with MCM9L, but the basic trends are parallel, suggesting that splicing and not 
transcription provides for these differences. 
2.1.2.4 MCM9 Isoform Expression Increases During Crosslink Damage 
After two recent reports that implicated MCM9 in the homologous recombination or crosslink 
repair pathways (74, 76), we assessed the expression profiles of MCM9M and MCM9L after 
exposure to mitomycin C (MMC) or hydroxyurea (HU) treatment. We exposed HeLa cells to 2 
μg/mL MMC for 6 hours or 150 μM HU for 48 hours and individually quantified the expression 
levels of MCM9M and MCM9L. MMC induces DNA crosslinking, causing replication to stall, 
forks to collapse, and the occurrence of subsequent double strand DNA breaks. Treatment with 
HU at these concentrations (136) acts to deplete dNTP pools stalling replication forks without 
significant double strand breaks (137). Both MCM9 isoforms show increases in expression after 
MMC exposure, although only changes in MCM9L are statistically significant (Table 2.3, Fig. 
2.9), as indicated by p-values (* = p < 0.05). The expression of MCM9M has a 1.5-log increase 
while MCML has a 5-log increase. On the other hand, treatment of cells with HU has no significant 
effect on the expression of either MCM9 isoform (Fig. 2.9).  
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Table 2.3: HeLa qRT-PCR ΔCT Values Following MMC or HU Treatment 
Figure 2.9: MCM9L and MCM9M abundances following MMC or HU treatment. 
qRT-PCR experimental results from total RNA extracted from HeLa cells treated with 2 µg/ml of mitomycin C 
(MMC) for 6 hours, 150 µM hydroxyurea (HU) for 48 hours, or no treatment. GAPDH CT values were subtracted 
from MCM9 CT values giving reported ∆CT. Experiments performed in triplicate were used to calculate the standard 
deviations. Statistical significance (p-values) of the difference in MCM9 expression between MMC treated cells and 
untreated cells was evaluated for each MCM9 isoform (* = p < 0.05). 
In direct contrast to the work in Xenopus, multiple reports show that Mus musculus MCM9 
(MmMCM9) is not required for DNA replication or cell survival although MCM9-deficient mice 
ΔCT1 
Treatment MCM9L MCM9M 
Untreated 21.2 +/- 0.9 22.2 +/- 0.6 
MMC2 16.3 +/- 0.3 21.2 +/- 0.9 
HU3 21.7+/- 0.07 21.2 +/- 0.2 
1Averages were calculated from 
experiments performed in triplicate. 
2MMC – mitomycin C, 3HU – 
hydroxyurea. 
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had elevated genomic instabilities such as an increased occurrence of sex-specific cancers 
including carcinomas (74, 75). Qualitative RT-PCR analysis showed expression of MCM9S and 
MCM9L over a variety of tissue types and through early development, but did not quantify 
MCM9M expression (75). Genetic ablation mutants designed to target MCM9SL or MCM9L 
isoforms also unknowingly disrupted MCM9M and resulted in viable mice with germ cell losses 
and predispositions to cancer (74, 75). Similarly, MCM9 depleted chicken DT40 cells were viable 
but sensitive to DNA crosslinks. The effects of both mitomycin C and hydroxyurea on MCM9L 
expression quantified in this manuscript are consistent with the increased protein levels and foci 
found in DT40 cells and validate a transcriptional response of MCM9L to crosslink induced double 
strand breaks (76). Importantly, the combined findings have directly implicated MCM9L as a 
member of the homologous recombination machinery acting to repair DNA breaks or resolve 
complex DNA structures during replication, but it is not yet clear whether MCM9M also 
participates in this pathway. Future experiments will be aimed at detecting and separating MCM9 
protein isoforms and identifying their individual influences on DNA repair once appropriate 
antibodies are available.  It will be important to examine whether the unique C-terminal domain 
of MCM9L is responsible for directing activities through specific interactions and whether any 
potential role exists for MCM9M in cells. 
2.1.2.5 Analysis of Intron-Exon Boundaries of MCM9 
Bioinformatics has indicated that up to 90% of genes with multiple exons are involved in 
alternative splicing in the human genome (128), yet very few alternatively spliced products have 
been implicated directly in regulating eukaryotic DNA replication or repair (138). Alternative 
splicing can occur due to many molecular reasons, but both sequence based mechanisms and 
cis/trans acting elements that either positively or negatively regulate splicing are the predominant 
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theories (127, 139, 140). Conservation at both the 5’ and 3’ splice site junctions (AG │GU) is 
required for efficient sequence based splicing mechanisms (141, 142). The intron-exon junctions 
are essentially conserved in HsMCM9 (Fig. 2.10 and Table 2.4). Sequence logos shown in Fig. 
2.10 represent conservation at the intron-exon boundaries for HsMCM9 for the 3’ (Fig. 2.10A) 
and 5’ (Fig. 2.10B) splice site junctions shown in Table 2.4. Logos were made using Weblogo 
(http://weblogo.berkeley.edu). 
Exon No. 
Intron – exon boundaries 
(3’ splice site – 5’ splice site)
1 AUGAAU – UAUCAG guaaau
2 caucag GUUUGC – GAACAG guaaau
3 ugcuag GUUCAA – AAUCUG guaaga
4 uccuag GUGAUG - UUGCAG guuugu
5 uccuag GAAGGA – UCAGAG guuagu
6 uccuag GAGAAU – GUGCAG guauug
7 ccucag GUCUGA – GGCUGG guaaga
8 uggcag CCUCGU – AUAAAG guacgu
9 auacag GUUACC – CAGAAG gucuau
10 ucuuag CUCAUG – AUGCAG guaagg
11 cuucag GGAGGU – UGAAAG gugagg
12 cuacag GUUACA – UCAUAG      _
Table 2.4: Genomic sequence overlapping splice sites in HsMCM9 
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Figure 2.10 Conservation of exon-intron boundaries for HsMCM9.  
Sequence logos showing the conservation at all the intron-exon boundaries for HsMCM9 for the (A) 3’ and (B) 5’ 
splice site junctions shown in Supplemental Table 2. Logos were made using Weblogo (http://weblogo.berkeley.edu). 
The only slight anomaly occurs at the 3’ splice site of Exon 11 which has a G at the +2 
position instead of a U, although the +2 residue of the exon is not universally conserved nor 
required for efficient splicing (142). Instead of a sequence-based mechanism, alternative splicing 
of MCM9M is controlled by yet unidentified cis or trans acting elements that repress efficient 
splicing of exon 11.  
2.1.2.6 Evolutionary Analysis of MCM9 
Alternative splicing and exclusion of exon 11 will cause a frame shift when translating from exon 
10 directly to exon 12, resulting in a premature stop codon at 1944 bp at the beginning of exon 12 
(Fig. 2.2A). This results in a deletion of the region encoding the unconserved C-terminal extension 
of MCM9L. The protein product translated from this alternatively spliced isoform (MCM9M) will 
be 648 amino acids in length, compared to the 1143 amino acid full length protein (MCM9L) with 
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a long C-terminal extension (Fig. 2.2B). MCM9M retains all of the conserved DNA and ATP 
binding motifs and is more consistent in size with the rest of the MCM family. Although we have 
attempted to detect protein levels of MCM9 using both custom and commercial antibodies 
targeting the N-terminal domains, we have been unable to reproducibly or specifically detect a 
band corresponding to 72 kDa (MCM9M) or 127 kDa (MCM9L) from a variety of cell types. 
Previous successful detection of MCM9 utilized custom antibodies specifically targeting the C-
terminal domain present only in MCM9L (74, 76). 
The C-terminal extension of MCM9L has no known homology or motif that would predict 
function but may be important for binding other factors (32, 67). After searching the database and 
aligning sequences using CLUSTAL W2 (http://www.ebi.ac.uk/Tools/clustalw2), we found an 
expressed sequence tag (EST XP_003586510) from Bos taurus that is extremely similar to 
HsMCM9M (Fig. 2.11A). The predicted protein sequence of fully spliced BtMCM9 with 13 exons 
contains 1139 amino acids but does not include the C-terminal amino acid sequence from the EST. 
After examination of the genomic sequence (143), it is clear that this EST is the result of alternative 
splicing similar to HsMCM9M. In this case, exon 12 was skipped and exons 11 and 13 were spliced 
producing a frame shift and resulting in the predicted protein sequence from the EST. The result 
is an extremely similar alternatively spliced isoform of MCM9M between humans and cattle. 
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Figure 2.11 MCM9M C-terminus sequence alignment. 
Alignment was constructed using CLUSTAL W2 (http://www.ebi.ac.uk/Tools/clustalw2). Grouped are 
representatives from animalia (blue), fungi (red), and plantae (green). Conserved residues are only highlighted as 
related to HsaMCM9M. Color coded boxes for absolutely conserved residues (orange) and highly conserved residues 
(yellow) are shown. A) Alternative splicing of specific exons is shown for Hsa, Homo sapiens and Bta, Bos Taurus 
MCM9M. B) Incomplete splicing of Dre, Danio rerio MCM9 isoforms that either excludes or includes coding from 
exon 12. C) Examples of fully spliced but comparatively medium MCM9M isoforms from Fungi: Bde, 
Batrachochytrium dendrobatidis or Plants: Rco, Ricinus communis; Ptr, Populus trichocarpa; Ath, Arabidopsis 
thaliana; Vvi, Vitis vinifera; Bdi, Brachypodium distachyon; Osa, Oryza sativa. 
Multiple isoforms of MCM9 also exist in Zebrafish (Danio rerio) where splicing either 
includes or excludes the terminal 3’ exon (Fig. 2.11B). For isoform 1 (DreMCM91), exon 12 is 
not efficiently spliced to exon 11 resulting in an early stop codon in the intervening intron region 
and is similar in size to HsMCM9M. Isoform 2 (DreMCM92) is completely spliced and translated 
with 1135 amino acids similar in length to HsMCM9L. Interestingly, analyses of plant genomes 
have also revealed predicted protein products sized similarly to MCM9M with 646 amino acids for 
Arabidopsis thaliana (AthMCM9) and 681 amino acids for Populus trichocarpa (PtrMCM9) but 
without conservation of animal MCM9 intron-exon boundaries or coding for the long C-terminal 
tail found in HsMCM9L (144). Further, we identified fungi (Batrachochytrium dendrobatidis) and 
other plant genomes with conserved and shorter C-terminal regions (Fig. 2.11C). MCM9 proteins 
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from these other eukaryotes not only have a similar size, but they also have some conservation of 
the predicted amino acid sequence at the C-terminus to HsMCM9M and DreMCM91. Due to the 
translational frame shift that occurs as a result of alternative splicing, this region of HsMCM9M is 
unique and not present in HsMCM9L. More complete amino acid homology at the C-terminus 
would be predicted if an additional isoform of HsMCM9 were to be detected that lacks splicing to 
the terminal exon 12. Therefore, evolution of MCM9 seems to have most recently occurred at the 
3’ end of the pre-mRNA transcript either through addition of the terminal exon, alternative 
splicing, or both. 
Fig. 2.11 shows grouped representatives from animalia (blue), fungi (red), and plantae 
(green). Boxes are color coded for absolutely conserved residues (orange) and highly conserved 
residues (yellow). Alternative splicing of specific exons is shown in Fig. 2.11A for Hsa, Homo 
sapiens and Bta, Bos taurus MCM9M. Fig. 2.11B shows incomplete splicing of Dre, Danio rerio 
MCM9 isoforms that either excludes or includes coding from exon 12. Fig. 2.11C shows examples 
of fully spliced but similarly sized MCM9M isoforms from Fungi: Bde, Batrachochytrium 
dendrobatidis or Plants: Rco, Ricinus communis; Ptr, Populus trichocarpa; Ath, Arabidopsis 
thaliana; Vvi, Vitis vinifera; Bdi, Brachypodium distachyon; Osa, Oryza sativa. 
2.1.3 Conclusion 
Although both HsMCM9M and HsMCM9L are expressed in a variety of cell and tissue types at a 
similar but low relative abundance, their cellular importance has only been revealed recently 
though a variety of knockout studies (74-76). Although we and others (67) suspect that the long 
C-terminal extension of MCM9L will be important for directing other protein interactions, both 
isoforms contain the essential motifs seen in other ATPases and DNA helicases. Further studies of 
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the enzymatic roles and regulation of both MCM9M and MCM9L protein isoforms in controlling 
DNA replication initiation or repair are needed to identify the mechanisms of action, and future 
experiments should be designed to differentiate between the multiple MCM9 isoforms to describe 
their individual roles. 
2.1.4 Experimental Procedures 
2.1.4.1 Materials 
Fetal bovine serum and Dulbecco’s Modified Eagle Medium (DMEM) supplemented with D-
glucose, L-glutamine and sodium pyruvate were from Atlanta Biologicals (Atlanta, GA). 
Penicillin-streptomycin and trypsin were from Invitrogen (Carlsbad, CA). Adult human cervix 
RNA was from Agilent Technologies (Santa Clara, CA). Nocodazole and hydroxyurea were from 
Fisher Scientific (Waltham, MA) and Mitomycin C was from Roche (Indianapolis, IN).  Taq DNA 
polymerase was from Bioline (Tauton, MA). Propidium iodide was from Sigma-Aldrich (St. 
Louis, MO). Ultraspec RNA isolation reagent was from Biotecx (Houston, TX). iScript One-Step 
RT-PCR Kit with SYBR Green was from Bio-Rad (Hercules, CA, USA). M-MuLV reverse 
transcriptase was from New England Biolabs. All other reagents were analytical grade or better.  
46 
Table 2.5: Oligonucleotides Used to Amplify MCM9 Isoforms. 
2.1.4.2 Human Cell Culture and RNA Isolation 
Cervical cancer (HeLa), lung cancer (A549), head and neck cancer (PCI-13), breast cancer (MDA-
MB-231 and MCF-7) and normal skin keratinocyte (HaCaT) cell lines were maintained in a 
humidified 5% CO2 incubator at 37°C. Cells were cultured in Dulbecco’s Modified Eagle Medium 
supplemented with 4.5 g/L D-glucose, 4.5 g/L L-glutamine and 4.5 g/L sodium pyruvate, 10% 
fetal bovine serum and 5% penicillin-streptomycin. Mitomycin C at 300 nM was added and cells 
were incubated for six hours, before washing and harvesting. Hydroxyurea at 150 μM was added 
to the media for 48 hours before washing and harvesting.  Cells were grown, harvested by 
trypsinization, and total RNA was extracted using the Ultraspec RNA isolation system (Biotecx, 
Houston, TX) according to the manufacturer’s instructions. Total RNA concentrations were 
calculated from the absorbance at 260 nm using a DU730 UV-visible spectrophotometer 
(Beckman Coulter Inc., Brea, CA).  
2.1.4.3 Semi-quantitative RT-PCR Detection of MCM9 Splice Variants 
cDNA was generated from total RNA using reverse transcriptase according to the manufacturer’s 
instructions. Four regions of MCM9 (E1-E4, E3-E6, E4-E10, and E9-E12) were specifically 
DNA Primers Sequence (5’-3’) 
E9Fa 5’-GATGAAAACCTATTTCTGCCTCAT-3’
E11R 5’-GCATTCACACCTCCTAGCAGTGCA-3’
E11SkipR 5’-CTCTGATTCTGTAACCTGCATT-3’
E9Fb 5’-CTCATAAGGAATCTGCAGCCCACACT-3’
E12R 5’-AGTAGTCTCTACCTCCAATACCCGTGGTT-3’
GAPDHF 5’-CAGCCTCAAGATCATCAGCA-3’
GAPDHR 
E1F 
5’-TGTGGTCATGAGTCCTTCCA-3’ 
5’-GATCTCGAGCATGAATAGCGATCAAGTTACACTGG3’
E3F 5’-GGTTCAAAGGCTATCTGTTGGAAGTAT-3’
E4R 
E5F 
E5R 
E6R 
E10R 
5’-TGCATTACAATCCCGTAAATAGTGAGG-3’ 
5’-GGAATGTAATATTGGCTAGCTTGTGCC-3’ 
5’-GCTCTTATAGTATTCCCAAAAATCTTCG-3’ 
5’-CCCAACCAATAAAAGATGAGATTCTCCT-3’ 
5’-GTTACAGTATCACGAAACATCAGGCG-3’ 
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amplified from cDNA using Taq. The forward and reverse primers (sequences in Table 5) were 
designed to overlap exons in the amplified regions. The A-tailed products of MCM9M and MCM9L 
were cloned into pGEM-T (Promega, Fitchburg, WI) and sequenced using the DNA sequencing 
facility at the University of Pittsburgh. For HeLa, A549, PCI-13, MDA-MB-231, MCF-7, and 
HaCaT cDNA, two sets of primers were used to specifically amplify each isoform. A single 
forward primer complementary to exon 9 (E9Fa) was used for amplification of both isoforms. A 
reverse primer specific to exon 11 (E11R) was used to amplify MCM9L and a reverse primer 
complementary to the region bridging exons 10 and 12 (E11SkipR) was used to amplify MCM9M. 
2.1.4.4 Quantitative Real-Time Reverse Transcriptase PCR (qRT-PCR) 
Human cells were grown and harvested by trypsinization. DNaseI-treated total RNA (8 µg) was 
subjected to qRT-PCR analysis using iScript One-Step RT-PCR Kit with SYBR Green (Bio-Rad, 
Hercules, CA, USA) and the real-time thermocycler iQ5 (Bio-Rad, Hercules, CA, USA). GAPDH 
was used as a reference gene. For qRT-PCR analysis of MCM9L and MCM9M, oligos E11R and 
E11SkipR were used, respectively with E9Fa (Table 2.5). For amplification of reference 
housekeeping gene GAPDH, GAPDHF and GAPDHR were used and for simultaneous 
amplification of MCM9S, MCM9M and MCM9L, oligos E3F and E5R were used (Table 2.5). The 
cycle threshold or CT value was determined for each amplified RNA sample and is the number of 
PCR cycles completed when the amplification curve intersects a specified threshold value. qRT-
PCR was performed in triplicate on each plate and relative expression of mRNAs was evaluated 
by the difference in cycle threshold values from GAPDH (∆CT) or between isoforms (∆∆CT) from 
at least three independent experiments (100). For all sets of data, p-values were calculated 
comparing the ∆CT value for MCM9M with that for MCM9L or between different cell samples for 
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the same isoform using a Student’s t-test in Excel. A p-value of <0.05 was considered statistically 
significant. The abundance of each target mRNA was determined by ΔCT=(CT(TARGET)-CT(GAPDH)) 
or ΔΔCT=ΔCT(TARGET1)-ΔCT(TARGET2). 
HeLa S-Phase and G2/M Synchronization HeLa cells were synchronized at the beginning 
of S-phase using a double thymidine block. Adherent cells were grown to 40% confluency in 150 
cm2 flasks with 30 mL growth medium. A final concentration of 2 mM thymidine (Sigma) was 
added and cells were incubated 20 hours. Cells were washed four times with 10 mL PBS, fresh 
growth medium was added and cells were incubated nine hours. 2 mM thymidine was added a 
second time, cells were incubated 15 hours, washed four times with PBS, and harvested by 
trypsinization at various time points following final release from thymidine with fresh DMEM. To 
produce cells synchronized at the G2 to M-phase boundary, cells were first synchronized using the 
double thymidine block described above, and following release from the second thymidine 
treatment, were washed four times with PBS and incubated in fresh growth medium 6 hours.  A 
final concentration of 0.2 μg/ml nocodazole was then added and cells were incubated 6 hours 
before being washed four times with PBS and harvested by trypsinization at various time points 
following release from nocodazole with fresh DMEM.  An asynchronous flask of cells was grown 
simultaneously and harvested at ~90% confluency by trypsinization. Total RNA was extracted and 
the concentration was determined as described above.  
2.1.4.5 Fluorescence Activated Cell Sorting (FACS) Analysis 
Samples of synchronized HeLa cells were permeabilized in 70% ethanol, resuspended in 75 μM 
propidium iodide, 10 mM Tris pH 7.5, 5 mM MgCl2 and 10 μg/ml RNAse A, and incubated at 
37°C for 30 min. Data from 10,000 or 20,000 events were collected with a FACSCalibur (Becton 
Dickinson Immunocytometry Systems, San Jose, CA) flow cytometer. Forward scatter (FSc) and 
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side scatter (SSc) were used to gate the cell populations, selecting for unaggregated live cells. 
Quantification of the cell populations occupying each cell cycle phase from the propidium iodide 
signal were determined using gating from the asynchronous sample and quantified using FlowJo 
software. 
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3.0  PATHOGENIC MUTATIONS OF MCM8 AND MCM92 
3.1 MCM8 AND MCM9 MUTATIONS UNDERLY OVARIAN FAILURE AND 
CHROMOSOMAL INSTABILITY 
3.1.1 Premature Ovarian Failure in Families with MCM8 or MCM9 Mutations 
The role of MCM2-7 in DNA replication elongation and prereplication complex formation has 
been established. (145) MCM8 and MCM9 are interacting partners that have not yet been 
characterized so extensively, although they have also been implicated in DNA replication. (69) A 
pathogenic mutation of MCM8 (c.446C>G; p. P149R) was identified in three sisters presenting 
with premature ovarian failure (POF) (Fig. 3.1), and two pathogenic mutations in MCM9 
(c.1732+2T>C and c.394C>T) (Fig. 3.2) in two separate families, whose daughters also present 
with POF. These families will be referred to as Family A (MCM9 c.1732+2T>C), Family B 
(MCM9 c.394C>T) and Family C (MCM8 c.446C>G; p. P149R). 
2 This section is taken from “AlAsiri S, Basit S, Wood-Trageser MA, Yatsenko SA, 
Jeffries EP, et al. (2015). Exome sequencing reveals MCM8 mutation underlies ovarian 
failure and chromosomal instability. J. Clin. Invest. 125, 258-262.” and “Wood-Trageser 
Michelle A, Gurbuz F, Yatsenko Svetlana A, Jeffries Elizabeth P, Kotan LD, et al. (2014). 
MCM9 mutations are associated with ovarian failure, short stature, and chromosomal 
instability. Am. J. Hum. Genet. 95, 754-762.” Permission to reprint was obtained from 
Elsevier Journals. Jeffries was responsible for cloning the mutated forms of MCM8 and 
MCM9, and performing transfection and foci formation experiments, as well as assessing 
DNA binding activity of MCM8(1-368). 
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Figure 3.1 Pedigree of a family with three daughters afflicted by premature ovarian failure and homozygous for the 
MCM8 c.446C>G variant.  
(A) Family members are designated by Arabic numerals. Horizontal lines between individuals represent marriage. 
Double horizontal lines indicate consanguinity in a marriage. Vertical lines represent lineage. Below each individual, 
current age (if known) and MCM8 genotype are provided.  (B) Sanger sequencing was used to validate genotypes and 
representative chromatograms are shown. Individuals who are heterozygous for the c.446C>G MCM8 variant show 
overlapping C and G peaks (middle). Individuals homozygous for the c.446C>G MCM8 variant have a single G peak 
(bottom).  (C) MCM8 is encoded on chr20: 5,931,293-5,975,831 (NCBI37/hg19). The MCM8 c.446C>G variant in 
exon 5 (red arrow). Full boxes represent exons (blue = coding sequences, green = noncoding sequences). Introns are 
indicated as lines. MCM8 consists of an N-terminal DNA binding domain and AAA+ core domain. The c.446C>G 
substitution causes a change in the amino acid sequence, p.P149R, within the predicted DNA binding domain (red 
arrow).  MCM8 p.E341K (green arrow) is located within the N-terminal hairpin of the DNA binding domain. All 
domains are color coded with the homology model (Figure 3.12). NHP: N-terminal hairpin; WA: Walker A; WB: 
Walker B; S1: Sensor-1; RF: Arginine Finger; S2: Sensor-2. 
Premature ovarian failure (POF) affects 1-4% of women, and is defined as a cessation of 
menses prior to age 40, with elevated follicle stimulating hormone (FSH) and low serum estradiol 
levels (130). Women with POF present with amenorrhea (primary or secondary), and 
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hypoestrogenic symptoms (i.e. hot flashes, vaginal dryness, premature osteoporosis). POF is 
genetically heterogeneous (131), with few genes identified, and can be idiopathic and non-
syndromic or part of a genetic syndrome.  
Three independent consanguineous families (Family A, Family B and Family C) presented 
separately for evaluation of their daughters. Affected daughters in these families experience 
amenorrhea as well as various other symptoms of POF. In the investigation of the cause of 
symptoms in Families A and B, peripheral blood samples were obtained from affected (AII4, AII6, 
and BII1) and unaffected family members (AI1, AI2, AII1, AII2, AII3, AII5, AII7, BI1, BI2, BII2, 
BII3, and BII4). The study was approved by the Ethics Committee of Cukurova University, Faculty 
of Medicine and informed written consent was obtained from all participating subjects.  
Two sisters in Family A and one sister in Family B presented with amenorrhea, as well as 
short stature and a 46,XX karyotype, all symptoms of POF. A combination of single nucleotide 
polymorphism arrays, comparative genomic hybridization arrays, and whole exome sequencing 
analyses identified homozygous pathogenic variants in MCM9 in affected sisters of both families. 
In Family A, the MCM9 c.1732+2T>C variant converts a splice donor site from GT to GC. The 
splice site mutation causes abnormal alternative splicing that results in transcripts predicted to 
encode deleted and truncated forms of MCM9 protein. While wild-type MCM9 readily forms foci 
at sites of DNA damage, the protein resulting from the mutation in which exon 9 is skipped is 
unable to form damage-induced foci. In Family B, the MCM9 c.394C>T variant inserts a stop 
codon in exon 2 (p.R132X) with a predicted loss of functional MCM9 protein. Chromosome break 
repair was impaired in lymphocytes from affected as compared to unaffected females in both 
families, consistent with MCM9 gene function in homologous recombination. Autosomal recessive 
variants in MCM9 cause a new genomic instability syndrome associated with hypergonadotropic 
53 
hypogonadism and short stature. Preferential sensitivity of the germline meiosis to MCM9 
functional deficiency, as well as compromised DNA repair in the somatic component, likely 
account for the ovarian failure and short stature.  
Three sisters (IV-1, IV-6, and IV-9) from Family C are also affected by POF (Fig. 3.1). All 
three sisters have a normal 46,XX karyotype, elevated FSH levels, infantile uteri, and small ovaries 
(Table 3.1). Secondary sexual characteristics were delayed. All three probands are currently 
treated with estrogen and progesterone replacement therapy and experiencing regular menstrual 
cycles. All three patients were also diagnosed with hypothyroidism and responded to thyroxine. 
The mother (III-2) entered menarche at age 14, reported normal pubertal development, regular 
menstrual periods (26-28 day menstrual cycles) until her mid-40s, and her last recorded menstrual 
period was at the age of 49. There is no known family history of anemia, blood dyscrasias, 
photosensitivity, immunodeficiency, or malignancies. We ruled out autoimmune 
polyendocrinopathy-candidiasis-ectodermal-dystrophy syndrome (APECED [MIM 240300]) by 
the absence of mucocutaneous candidiasis, hypocalcemia, hypoglycemia, hypotension, vitiligo, 
alopecia, anemia, or hepatitis in affected daughters. We did not identify pathogenic variants in the 
gene that causes APECED, AIRE (MIM 607358). Anti-thyroid and anti-adrenal gland antibodies 
were not detected in affected daughters. In summary, the three daughters had idiopathic 
hypergonadotropic primary amenorrhea with hypothyroidism, atrophic ovaries, and normal female 
karyotype.   
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Figure 3.2 Pathogenic homozygous recessive variants in MCM9 in two consanguineous families of Turkish descent.  
(A-B) Each generation is designated by a Roman numeral and each family member by an Arabic numeral. Circles 
represent female family members while squares represent males. Filled circles represent family members affected by 
primary amenorrhea. Horizontal lines between individuals represent marriage. Double horizontal lines indicate 
consanguinity in a married couple. Vertical lines represent lineage. Below each individual, their MCM9 genotype is 
provided.  WT denotes wild type allele. MT indicates either (A) the c.1732+2T>C variant or (B) the c. 394C>T variant 
of the MCM9 gene.  Samples utilized for WES are indicated by an asterisk. Sanger sequencing was used to validate 
genotypes and representative chromatograms are shown. (A-B) Genotype is indicated as WT/WT, WT/MT or MT/MT 
for each individual.   (B) Chromatograms shown are from sequencing in the reverse orientation of the gene. Arrows 
point to the nucleotide peak of interest. (C) The MCM9 c.1732+2T>C splice variant lies in the splice donor site of 
exon 9 (red arrow). The c.394C>T mutation lies near the 5’ end of exon 2 (blue arrow). Exons are indicated as full 
boxes (black). Alternative splice isoforms of MCM9 either include or exclude Exon 11 (white). Introns are indicated 
as lines. (D) MCM9 consists of an N-terminal DNA binding domain and AAA+ core domain.  The c.1732+2T>C 
substitution is predicted to disrupt normal splicing after amino acid 577. The c.394C>T mutation causes insertion of 
a stop codon in the place of an arginine at p.132. This likely results in a truncated protein, if one is produced. Yellow 
box – Zn Finger Domain, Red box - Walker A, blue box - Walker B, purple box - Arginine finger. NHP: N-terminal 
hairpin; ZF: Zinc Finger; WA: Walker A; WB: Walker B; RF: Arginine Finger; S1: Sensor-1; S2: Sensor-2. 
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In family A, parents are first degree cousins. Mother (AI2) entered menarche at age 15, 
reported normal pubertal development and continues to have regular menstrual periods (26-28 day 
menstrual cycles) at 49 years of age. She had no difficulties becoming pregnant and is currently 
150 cm tall and weighs 68 kg. She gave birth to six girls and one boy. Two of her daughters (AII4 
and AII6) presented initially for clinical evaluation due to a Turner-like phenotype due to primary 
amenorrhea and short stature (Fig. 3.2A). The proband (AII4, Fig. 3.2A) is now a 23 year old 
woman who presented with hypergonadotropic primary amenorrhea and short stature at the age of 
16, and had normal 46,XX karyotype (Table 3.2). Her estradiol levels were low at 7.4 pg/ml with 
elevated luteinizing hormone (LH; 33.9 mIU/ml) and post-menopausal levels of FSH (73 mIU/ml). 
Her prolactin level was 9.7 ng/ml (reference range: 3.3-26.7). She had short stature (136.1 cm, -
4.3 SD) and low weight (42.3 kg, -2.4 SD). Ovaries were not identified on pelvic ultrasound and 
the uterus was infantile. The patient is currently regularly menstruating on combined estrogen-
progestin replacement therapy and at 23 years of age has achieved a bone age of 18 years, pubic 
hair stage V, and breast development Tanner stage V. The second affected individual in Family A 
is a 19 year-old woman (AII6, Fig. 3.2A), who was diagnosed at 16 years of age with 
hypergonadotropic primary amenorrhea, short stature and absent breast development. She 
presented with short stature (height = 134.4 cm, -4.8 SD), low weight (29.4 kg, -5.7 SD), and a 
bone age of 12 years (Table 3.2). Her basal estradiol level was low (5 pg/ml) with elevated LH 
and FSH levels (47.3 and 122.5 mIU/ml, respectively). Prolactin levels were within the normal 
range at 7.1 ng/ml.  Ovaries were not detected on pelvic ultrasound. Cytogenetic studies showed 
46,XX karyotype. She had stage III pubic hair development, stage II axillary hair, and absent breast 
development. She is currently treated with estrogen and progesterone replacement therapy, and 
experiencing regular menstrual cycles, and breast development. There is no known family history 
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of anemia, blood dyscrasias, photosensitivity, immunodeficiency, or malignancies. In summary, 
the two sisters had hypergonadotropic primary amenorrhea, short stature, normal uterine anatomy 
with atrophic ovaries, and normal female karyotype. Three unaffected sisters (AII2, AII3, and 
AII5), age 22-26, all entered menarche between the ages of 12 and 13 and are currently 
experiencing regular menstrual cycles. The youngest sister, AII7 presented with developmental 
delay and was excluded from further genetic analyses due to abnormal de novo chromosomal 
microarray findings (Figure 3.3).  
Figure 3.3 Complex de novo chromosomal abnormality in AII7. 
AII7 presented with developmental delay (Wechsler intelligence scale for children, score = 62) and short stature. She 
has cubitis valgus, shield chest, widely-spaced nipples, nevi on the face, long eyelashes, and anteverted nares, with 
normal female external genitalia. Use of CGH array on this patient identified a large 19 Mb duplication (12,258,762-
31,345,582), a smaller, 0.7 Mb duplication (33,952,093-34,660,948) and a small deletion (160 kb; 47,912,081-
48,073,069) all on chromosome 11 p. The G-banding karyotype showed a 46,XX, dup11p15. This was a de novo 
complex rearrangement, as neither parent carried this complex rearrangement. Black dots represent normal copy 
number. Blue, green and pink dots represent loss of normal copy number (deletion). Red dots indicate more than 
normal copy number. Genomic coordinates are based on hg19. 
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Normal Rangea IV-1 IV-6 IV-9 
FSH (IU/ml) 1.8-22.5b 73.25 95.09 42.13 
AMH (ng/ml) <6.9c <0.6 <0.6 <0.6 
LH (IU/ml) 1.2-100b 22.10 28.93 12.05 
Estradiol (pg/ml) 30 to 300b 1.11 10.37 10.82 
TSH (mIU/ml) 0.3-5.0b 7.68 6.51 6.24 
Prolactin (ng/ml) 3-27 2.5 11.93 14.67 
Uterine Volume (cm3)d 20-100(146) 18.5 14.6 3.7 
Right Ovarian Volume (cm3) 6.6±0.19(147) Not visualized Not visualized 0.7 
Left Ovarian Volume (cm3) 6.6±0.19(147) 4.3 2.7 0.4 
Anti-Thyroid Antibodies Negative Negative Negative Negative 
Karyotype 46,XX 46,XX 46,XX 46,XX 
aAll hormone measures provided were prior to hormone replacement therapy. 
bMayo Clinic, Mayo Medical Laboratories, Rochester, MN. 
cReference Range for Adult Females, Esoterix Lab, Calabasas, CA. 
dUterine volume calculated by using the formula for prolate ellipsoid: longitudinal diameter x 
anterioposterior diameter x transverse diameter x 0.5233. Range based on Tanner stage 4-5 or adult 
uterine volumes. 
Table 3.1: Clinical Laboratory Investigations of Affected Family C Daughters (IV-1, IV-6, and IV-9). 
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Normal Range AI2 AII4 AII6 BI2 BII1 
Current Age (years) - 49 23 19 39 18 
Age at Menarche 
(years) 
- 15 - - 13 - 
Age at Diagnosis 
(years) 
- - 16 16 - 16 
Karyotype - 46,XX 46,XX - 46,XX 
Pre-hormone Replacement Therapy 
FSH (mIU/ml) 1.8-22.5* - 73 122.5 - 140.1 
LH (mIU/ml) 1.2-100* - 33.9 47.3 - 32.42 
Estradiol (pg/ml) 30 to 300* - 7.4 5 - 6 
Prolactin (ng/ml) 3.3-26.7 - 9.7 7.08 - 12.58 
Height (cm) 158-168** 150 136.1 134.4 141.5 
Weight (kg) 47-62** 68 42.3 29.4 61 35.5 
IGF-1 (ng/ml) 130-595*** - N/A 408 - 200 
IGFBP-3 ( g/ml) 3.4-9.5*** - N/A 4.81 - 3.76 
GH (ng/ml) 0.01-3.61** - N/A 9.5 - 3.03 
Uterine Length (cm) 7.3±0.8(148) - Not 
visible 
Not 
visible 
- 2.9 
Ovarian Volume (cm3) 6.6f - Not 
visible 
Not 
visible 
- Not 
visible 
Tanner Stage (Pubic 
Hair) 
- - 2 2-3 - 2-3 
Tanner Stage (Breast) - - 1 1 - 1 
Bone Age (years) - - 11 12 - 11 
Post-hormone Replacement Therapy 
FSH (mIU/ml) 1.8-22.5* - 30.13 159.2 - 34.1 
LH (mIU/ml) 1.2-100* - 30.15 50.1 - 4.3 
Estradiol (pg/ml) 30 to 300* - 73.1 19 - <20 
Height (cm) 158-168** - 144.3 143.1 - 150.4 
Weight (kg) 47-62** - 46 42.3 - 41.7 
Tanner Stage (Pubic 
Hair) 
- - 5 5 - 5 
Tanner Stage (Breast) - - 5 5 - 5 
Bone Age (years) - - 18 17 - 16 
*Mayo Clinic, Mayo Medical Laboratories, Rochester, MN. **Ranges based on CDC Clinical Growth
Charts. ***Reference Range for 16 year old female, Mayo Clinic, Mayo Medical Laboratories. 
Table 3.2 Clinical Laboratory Investigations of Affected Individuals Prior to Hormone Replacement Therapy, 
Families A and B 
An unrelated Family B presented with a 16-year old girl (Fig. 3.2B) who had primary 
amenorrhea, short stature, and lacked breast development. Her past medical history was otherwise 
unremarkable. On physical examination she was found to have minimal breast development, stage 
III (P3) pubic hair, and stage II axillary hair development. She had short stature with a height of 
141.5 cm (-3.27 SD), weighed 35.5 kg (-3.65 SD), and her bone age was 11 years (Table 3.2). 
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Pelvic ultrasonography revealed an infantile uterus (about 2.9 cm in length, expected length=7.3 
± 0.8 cm) and no visible ovaries. Her basal estradiol level was low (6 pg/ml) with elevated LH and 
FSH levels (respectively 32.42 and 140.07 mIU/ml). She had a normal 46,XX female karyotype. 
Prolactin levels measured in the normal range at 12.58 ng/ml and 8.11 ng/ml (reference range: 
3.34-26.72). She has regular menstrual bleeding with combined estrogen-progestin replacement 
therapy. Hormone replacement therapy also induced growth to a height of 150.4 cm (-1.9 SD), a 
weight of 41.7 kg (-2.4 SD), and breast development to Tanner stage V. The proband’s mother 
(BI2) is currently 39 years of age. She exhibited signs of thelarche at 10 years of age and had 
normal first menarche at 13 years of age. She continues to cycle normally. She is 157.5 cm tall and 
weighs 61 kg. The 13-year-old unaffected sister (subject BII3) had normal first menarche at 12 
years of age and has had regular menstrual cycles. Her height was 150.1 cm (-1.0 SD), her weight 
was 37.4 kg (-1.1 SD). Additionally, the proband has two healthy brothers (BII2 and BII4) that 
have no known medical problems. 
A nonsynonymous SNP in exon 9 of MCM8 (rs16991615), p.E341K, has been highly 
associated with the age of natural menopause through genome-wide association studies is strongly 
implicates DNA repair pathways (81, 83-87). The mutation is contained within the N-terminal 
hairpin of the DNA binding domain of MCM8 (Fig. 3.14), predicted to be essential for the DNA 
binding activity of the protein.  
3.1.2 Research Design 
3.1.2.1 Identification of MCM8 and MCM9 Mutations 
To identify the genetic cause of ovarian dysgenesis and primary amenorrhea in Family A, we 
performed DNA copy number analysis and homozygosity mapping in two affected individuals 
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(AII4 and AII6) as well as four unaffected (AII2, AII3, AII5, AII7) female siblings. Two 
contiguous regions of homozygosity were identified on chromosomes 1 and 6: 1p34.3 
(chr1:35,187,876-36,929,988; hg19) and 6q21-q22.33 (chr6:114,543,815-127,262,938; 
NCBI37/hg19), that were shared by the two affected daughters but not shared by unaffected 
individuals (Fig. 3.4). These two regions of homozygosity did not contain genes known to be 
involved in human ovarian failure and short stature. We therefore undertook an unbiased whole 
exome sequencing (WES) approach to identify pathogenic variants. 
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Table 3.3 Whole Exome Sequencing Variant Calls in Families A and B 
Gene Location Coding Mutation 
Protein 
Mutation dbSNP 
C
on
se
rv
at
io
n 
(P
hy
lo
P)
 
Protein Change 
Prediction 
SIFT Poly-phen2 
Family A 
CEP85L chr6: 118887215 c.A497T p.D166V rs9489444 N D P 
GEMIN4 chr17: 648664 c.C2619A p.H873Q
rs19177812
7 N/A N/A B 
MCM9 chr6: 119149088 
c.1732+2
T>C 
Splicing 
mutation - N/A N/A N/A 
Family B 
AZI1 chr17: 79169670 c.G1981A p.E661K rs61741549 C T B 
CCDC137 chr17: 79639666 c.C802T p.R268W
rs11269964
8 N D D 
DNAH14 chr1: 225237950 c.A1951G p.I651V rs78320839 N/A N/A N/A 
DNAH17 chr17: 76481652 c.C7463T p.T2488M
rs37438791
3 N/A N/A N/A 
ENGASE chr17: 77080696 c.G1519A p.V507I
rs20179280
0 C T B 
FER1L6 chr8: 124992866 c.C1225T p.R409W
rs20125412
9 C N/A N/A 
MCM9 chr6: 119245203 c.C394T p.R132X - C N/A N/A 
MUC5B chr11: 1271321 c.C13211G p.A4404G rs2943517 N/A N/A N/A 
OXLD1 chr17: 79632592 c.C83A p.P28Q
rs11195939
3 N T B 
ST6GALN
AC1 
chr17: 
74622747 c.G1297A p.V433M
rs14030002
5 C D P 
TMEM63
A 
chr1: 
226055624 c.G478A p.V160I
rs11560089
6 N T B 
Abbreviations for PhyloP, SIFT, and Polyphen-2: C = Conserved; N = Not Conserved; D = 
Damaging; P=Probably Damaging; B = Benign; T = Tolerated. 
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Figure 3.4 Region of homozygosity on chromosome 6 in Family A.  
Use of a SurePrint G3 ISCA design CGH+SNP, 4x180K oligonucleotide microarray (Agilent, Santa Clara, CA) 
allowed the identification of a region of homozygosity between chr6: 114,543,815-127,262,938 (hg19, red lines) that 
was found both in AII4 and AII6 (affected sisters) that was not present in AII3 and AII2 (unaffected sisters). AII4 and 
AII6 show an absence of dots down the middle of the plot which are present in AII3 and AII2. 
WES was conducted on three unaffected daughters (AII2, AII3, AII5), both parents (AII1 
and AII2) and two affected siblings (AII4 and AII6). Three variants in CEP85L (6q22.31), 
GEMIN4 (17p13.3), and MCM9 (6q22.31), fit the homozygous autosomal recessive model (Table 
3.3). Of these three, CEP85L and MCM9 mapped to the region of homozygosity shared by affected 
sisters on chromosome 6 (Fig. 3.4).  Homozygosity in AII4 and AII6 is indicated by the absence 
of dots down the center of the plot for these two patients. The CEP85L variant in affected sisters 
(c.A497T, p.D166V) was previously reported as a SNP (rs9489444), with 3% allele frequency, 
and was not conserved across species. We therefore eliminated CEP85L as a likely cause of 
observed phenotype. 
The c.1732+2T>C variant in MCM9 remained as the only pathogenic variant in Family A. 
The MCM9 variant c.1732+2T>C (chr6:119,149,088, NCBI37/hg19) changed the highly 
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conserved splice donor site GT to GC located right after exon 9 (Fig. 3.2C, D). This variant has 
not been previously reported in either the Exome Variant Server or 1000 Genome databases.  
Figure 3.5 MCM9 c.1732+2T>C results in abnormal alternative splicing. 
(A) Schematic of primer design to detect splicing aberrations and band sizes of each product analyzed. Wild-type 
product is predicted to produce a 846 bp fragment and known alternative splicing of exon 11 results in a 700 bp 
fragment. These fragments were amplified in the heterozygote AI2, but not in homozygous AII6 individual. A 954 bp 
fragment is an abnormal splicing product that contains 108 bp of intron 9 and is predicted to introduce a premature 
stop codon.  A 646 bp fragment is an abnormal splicing product in which exon 9 is deleted and a smaller, 499 bp 
fragment lacks both exons 9 and 11. (B) Representative gel image of DNA products fractionated on agarose gel 
following PCR amplification of cDNA derived from RNA of lymphoblastoid cell lines from heterozygous mutation 
carrier, AI2, and from affected homozygous mutation carrier, AII6, using primers (shown in A, 1151 Forward: 5’ – 
GAT CTA CTA GTG CAG GTC TGA CG – 3’; 1996 Reverse: 5’ – GCA CAC TCT GAT TCT GTA ACC TTT – 
3’). 
We examined the effect of MCM9 c.1732+2T>C mutation on MCM9 RNA alternative 
splicing products. We predicted that loss of the exon 9 splice donor site would alter splicing 
downstream of exon 9 (corresponding to amino acid 577; Fig. 3.2C, D). Using oligonucleotide 
primers that bracket c.1151-1996 (exon 7 to exon 12) in MCM9 cDNA are expected to amplify a 
wild type 846 bp product as well as the 700 bp band resulting from exon 11 skipping, a known 
alternatively spliced mRNA variant from the wild type MCM9 locus (149) (Fig. 3.5A and 3.6B, 
C). The heterozygous mother contained the wild type (846 bp), alternative wild type (700 bp) 
product (faint), and three additional splicing products:  954 bp (faint), 646 bp, and 499 bp (faint) 
(Fig. 3.5A,B). The wild type 846 bp and 700 bp bands were absent from the homozygous 
daughter’s DNA but the three mutant products were detected. Sanger sequencing of the predicted 
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846 bp wild-type band contained exon 8, 9, and 10 in sequence, and the 700 bp alternative wild 
type product was lacking exon 11, as expected (Fig. 3.6A, B). Sequencing of the 954 bp band 
revealed an abnormal splicing product comprising exon 9 plus 108 bp of downstream intronic 
sequence spliced onto exon 10 (Fig. 3.6A). This intronic region ends at a cryptic splice site and is 
predicted to encode an additional 29 amino acids followed by a premature stop codon. This stop 
codon likely results in a truncated protein lacking the winged helix domain and unique C-terminal 
extension of MCM9. The 646 bp fragment was a result of abnormal splicing that skipped exon 9 
(Fig. 3.6C). Exon 9 encodes a portion of MCM9 that is homologous to the Sensor 2 domain of 
Archaeal MCM ATPase domain, which is predicted to be involved in ATP binding (60). The loss 
of exon 9 is predicted to delete 67 amino acids from the wild type MCM9 protein. The 499 bp 
fragment was a result of alternative splicing that skipped both exons 9 and 11 (Fig. 3.5A,B and 
3.6B,C). Our results show that MCM9 c.1732+2T>C genomic mutation causes abnormal splicing 
products predicted to disrupt MCM9 protein function.  
Figure 3.6 Sanger sequencing identified abnormal splice variants of MCM9 in family members carrying the 
c.1732+2T>C mutation.
Primers that bracket the c.1732+2T>C mutation were used to amplify cDNA from lymphoblastoid cells of family 
members AI2, heterozygous mother, and AII6, homozygous daughter. PCR products were fractionated on an agarose 
gel (as shown in Figure 3.5). The nucleotide sequence of each product was evaluated by Sanger sequencing. 
Representative chromatograms are shown for the DNA fragments that were identified. The 846 bp DNA fragment 
revealed the wild-type sequence containing exons 7, 8, 9, 10, 11, and 12 in order. (A) The largest DNA fragment, 954 
bp, is the result of abnormal splicing which includes exon 9, 108 bp of intron 9, and exon 10, in sequence. Intron 9 is 
1062 bp in size and contains a cryptic splice site at nucleotide 108.  (B) The 700 bp fragment revealed a loss of exon 
11 from the wild-type sequence, as had been previously described. (C) The 646 bp fragment was the result of abnormal 
splicing and revealed a loss of exon 9 from the wild-type sequence. The smallest fragment, 499 bp, revealed a loss of 
both exons 11 (B) and 9 (C). 
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In Family B, we conducted WES on the unaffected daughter (BII3), both parents (BI1 
and BI2), and the affected daughter (BII1). After variant filtration, eleven variants remained that 
fit the homozygous autosomal recessive model (Table 3.3). Of these eleven, only the MCM9 
(c.394C>T, chr6:119,245,203, NCBI37/hg19) variant was novel, while the rest were known 
SNPs. The MCM9 c.394C>T variant has not been previously reported in either the Exome 
Variant Server or 1000 Genome databases, it is highly conserved, and it results in insertion of a 
premature stop codon in exon 2 of MCM9, p.R132X (Fig. 3.2C, D). The MCM9 c.394C>T 
variant was verified by Sanger Sequencing (Fig. 3.2B, bottom) and was absent in 200 fertile 
women. 
Chromosome Coordinates (hg19) Siblings in Which Region Identified LOD Score 
Chr 1 2010994-4953528 Unaffected and Affected 1.53 
Chr 12 81229423-82251957 Unaffected and Affected -0.65 
Chr 19 21157697-28750407 Unaffected and Affected 0.66 
Chr 20 65288-1136217 Affected Only 1.58 
Chr 20 2163414-4313037 Affected Only 1.18 
Chr 20 4861939-6976715 Affected Only 2.77 
Table 3.4 Regions of Homozygosity Based on SNP Array, Family C 
In Family C, SNP analyses identified a 3.3 Mb region of homozygosity on chromosome 
20p13-p12.3 flanked by rs1547618 and rs1012891 present only in affected subjects (Table 3.4). 
No known POF genes lay in this interval and we undertook whole exome sequencing (WES) to 
identify pathogenic variants. WES revealed two non-synonymous variants, FERMT1 (MIM 
607900) and MCM8 (MIM 608187), which met autosomal recessive inheritance filter criteria and 
mapped to the region of homozygosity with the highest LOD score on chromosome 20.  The 
FERMT1 variant (NM_017671:c.293G>A, p.R98H) was previously reported (rs137862671) in 
public databases and is likely a benign variant. Pathogenic variants in FERMT1 cause Kindler 
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Syndrome (MIM 173650), and none of the manifestations of Kindler syndrome (i.e. congenital 
blistering, skin atrophy, photosensitivity, skin fragility, scaling) were reported in this family. 
Figure 3.7 Evolutionary comparison of the selected MCM8 region across species.  
CLUSTAL Omega web site (http://www.ebi.ac.uk/Tools/msa/) was used to align the sequences from MCM8 proteins 
in human (Homo, NP_001268449. 229 1), mouse (Mus, NP_079952.2), frog (Xenopus, NP_001089437.1) and the 
predicted zebrafish sequence (Danio, XP_002665161.2). p.P149R is found at the evolutionary conserved Proline 
(highlighted in yellow). 
The MCM8 (NM_032485) c.446C>G missense variant remained as the only candidate for 
the observed phenotype. MCM8 c.446C>G has not been reported in either the Exome Variant 
Server or 1000 Genomes databases.  The MCM8 c.446C>G variant was verified in the family by 
Sanger sequencing (Fig. 3.1B) and was absent in 200 fertile women. The resulting protein 
mutation, p.P149R, occurs at a highly conserved residue located in the N-terminal DNA binding 
domain of MCM8 (Fig. 3.1C, Fig. 3.7).  
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Patient 
Cell Number Control IV-1 IV-6 
1 0 0 0 
2 0 1 0 
3 0 0 0 
4 1 0 0 
5 0 0 0 
6 0 0 0 
7 0 0 0 
8 0 0 0 
9 0 0 0 
10 0 0 0 
Total Number of Breaks 1 1 0 
Ave. No. Breaks/ Cell 0.1 0.1 0 
Table 3.5 Chromosomal Breakage as Induced by DEB treatment in Patient Lymphocytes (Raw Data). 
3.1.2.2 Impairment of DNA Break Repair in Families A and C 
Fibroblasts from Mcm8 deficient mice show hypersensitivity to agents that induce dsDNA breaks 
and DNA crosslinks resulting in a higher number of broken chromosomes, a hallmark of genomic 
instability (74).  We assayed DNA repair capabilities of cultured fibroblasts derived from affected 
and unaffected family members (Fig. 3.8A-C) (150). Fibroblasts from unaffected sister IV-3 (WT 
genotype) showed few chromosome breaks at 150 nM and 300 nM concentrations of MMC (Fig. 
3.8A, D). Cells from III-2 (unaffected mother, heterozygous WT/MT) showed a significantly 
increased number of chromosomal breaks/cell when compared to IV-3 (unaffected sister, WT 
genotype) at all concentrations of MMC (Fig. 3.8B, D): 50 nM (0.9 ± 0.3 vs. 0.1 ± 0.1, p = 0.02), 
150 nM (5.3 ± 0.4 vs. 2.6 ± 0.3, p < 0.001), and 300 nM (8.1 ± 0.5 vs. 5.0 ± 0.4, p < 0.001). In 
both affected sisters (IV-1 and IV-6; homozygous MT/MT), the number of chromosomal 
breaks/cell was at least 8-10 fold higher than in heterozygote carriers (Fig. 3.8C, D, p < 0.01). At 
150 nM MMC, an average of 22.4 ± 1.5 and 15.4 ± 0.8 chromosome breaks/cell were observed for 
affected sisters IV-1 and IV-6, respectively (p < 0.001). More than 50 chromosomal breaks/cell 
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were observed at 300 nM of MMC exposure in cells from affected sisters IV-1 and IV-6 (p < 
0.001). In the majority of cells homozygous for the mutation, multiple complex chromosomal 
aberrations were observed (Fig. 3.8C, D). Therefore, MCM8 c.446C>G homozygous mutation 
impedes repair of MMC induced chromosomal breaks. Exposure of peripheral lymphocytes to 
diepoxybutane (0.1 µg/ml) did not cause chromosomal breakage in cells from the same family 
members  (IV-1 and IV-6) homozygous for the MCM8 c.446C>G mutation. Ten metaphase 
cells/patient were evaluated but the number of breaks detected was less than 0.2 breaks/cell (Table 
3.5). Diepoxybutane results suggest that MCM8 is not part of the Fanconi anemia DNA repair 
pathway. WES data analysis from affected sisters did not reveal additional variants that would 
affect protein function in genes known to be associated with chromosomal instability and ovarian 
failure (Table 3.6). 
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Gene Associated Syndrome Variant 
ATM Ataxia-telangiectasia Benign SNP 
BRCA1 Breast Cancer Benign SNP 
BRCA2 Fanconi Anemia, Wilms tumor, and cancers Benign SNP 
BRIP1 Fanconi anemia, Breast Cancer Benign SNP 
ERCC4 Fanconi anemia None 
FANCA Fanconi anemia None 
FANCB Fanconi anemia None 
FANCC Fanconi anemia None 
FANCD2 Fanconi anemia None 
FANCE Fanconi anemia None 
FANCF Fanconi anemia None 
FANCM Fanconi anemia None 
FMR1 Fanconi anemia None 
HGPS Hutchinson-Gilford progeria None 
MLH1 Mismatch repair cancer syndrome None 
MLH3 Colorectal Cancer, Endometrial Cancer Benign SNP 
MSH2 Mismatch repair cancer syndrome None 
MSH3 Endometrial carcinoma Benign SNP 
MSH6 Mismatch repair cancer syndrome Benign SNP 
NBN Nijmegen breakage syndrome Benign SNP 
NBS1 Nijmegen Breakage Syndrome None 
PALB2 Fanconi anemia None 
PHF9 Fanconi anemia None 
RAD50 Nijmegen breakage syndrome-like disorder None 
RAD51C Fanconi anemia None 
SLX4 Fanconi anemia None 
TP53 Multiple Cancers Benign SNP 
WRN Werner syndrome Benign SNP 
XPC Xeroderma pigmentosum Benign SNP 
XRCC9 Fanconi anemia None 
Table 3.6 WES Variants in genes known to be involved in chromosomal instability or primary amenorrhea, Family 
C. 
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Figure 3.8 MCM8 mutation impairs DNA break repair.  
Cells from homozygous MCM8 c.446C>G individuals have impaired ability to repair dsDNA breaks induced by 
MMC. A total of four experimental groups were treated with MMC for each sample. Representative metaphase cells 
treated with 300 nM MMC are shown from (A) healthy and fertile individual with MCM8 WT/WT genotype (family 
member IV-3), (B) unaffected WT/MT genotype (family member III-2), and (C) affected females homozygous for 
the MCM8 c.446C>G pathogenic variant (MT/MT genotype; family member IV-1). The number of chromosomal 
breaks counted was limited to 60 per cell and those with more were indicated as 60+ breaks/ cell. Error bars 
represented the standard error of the mean. * = p<0.01, ** = p<0.001, *** = p<0.0001. 
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Figure 3.9 Mutations in human MCM9 impair repair of MMC-induced chromosomal breaks. 
Homozygous MCM9 c.1732+2T>C and c.394C>T mutations associate with increased rate of chromosomal breakage. 
Peripheral blood lymphocytes from unaffected (wild-type or heterozygous carriers) and homozygous mutant 
individuals were stimulated by phytohaemagglutinin (PHA), cultured for 72 hours after treatment with 0 nM, 50 nM, 
150 nM, or 300 nM Mitomycin C (MMC), and metaphase chromosome breaks were quantified. (A-C) Representative 
figures of metaphase spreads from wild-type (A), homozygous mutant c.1732+2T>C (B) and homozygous mutant 
c.394C>T (C) are shown after treatment with 300 nM MMC. Homozygous mutant cells show extensive chromosome
damage with numerous breaks, non-homologous exchanges, chromatid deletions, complex aberrations, and acentric 
fragments (arrows) as compared to the wild-type.  The mean numbers of chromosomal breaks per cell were quantified 
for cells from Family A, c.1732+2T>C mutation (D) and Family B, c.394C>T mutation (E). Bar graphs show the 
mean number of breaks per cell (±SD) observed for each MMC concentration. At least ten metaphase cells were 
studied for affected (AII4, AII6, and BII1), unaffected (AII2, BII3, and BI2) family members, and a healthy fertile 
unrelated female (control). ANOVA for Single Factor variation was utilized to determine the effect of drug 
concentration on each cell line. Two-tailed T-tests assuming unequal variance were used to compare two cell lines at 
a single drug concentration.  ***, p<0.001. 
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Similar to MCM8, it has been established that during gametogenesis, MCM9 protein is 
critical for homologous recombination (HR) in the repair of DNA double-stranded breaks (DSBs) 
and stabilization of broken or stalled DNA replication forks (68-70, 74, 76, 151). In addition to 
gonadal failure, fibroblasts from MCM9 deficient mice show hypersensitivity to agents that induce 
DSBs and DNA crosslinks (i.e. ionizing radiation and MMC) resulting in a higher number of 
broken chromosomes, a hallmark of genomic instability.  We assayed DNA repair capabilities of 
lymphocytes derived from members of both Family A (Fig. 3.9A, B, D) and Family B (Fig. 3.9C, 
E). 
Treatment with 50 nM MMC induced significant numbers of chromosomal breaks only in 
cells homozygous for the p.R132X mutation from BII1 when compared to unrelated control (p = 
6.93x10-5) or heterozygous parent BI2 (p = 2.69x10-5; Fig. 3.9E). Treatment with 150 nM MMC 
revealed significantly more chromosomal breaks in cells from patients homozygous for the 
splicing mutation c.1732+2T>C and stop codon mutation p.R132X (AII4, AII6 or BII1) when 
compared with cells from an unrelated control (p = 2.6x10-7, p = 1.6x10-14, and p = 3.58x10-8, 
respectively) or heterozygous carriers (AII4 vs. AII2, p = 2.6x10-7; AII6 vs. AII2, p = 5.4x10-14; 
BII1 vs. BI2, p=3.24x10-8; Fig. 3.9D,E). Treatment with 300 nM MMC revealed a similar trend 
with significantly more chromosomal breaks in cells from affected AII4 or AII6 compared with 
control (p = 7.5x10-8 or p=1.6x10-7, respectively) or heterozygous AII2 (p = 1.6x10-7; Fig. 3.8D). 
Similarly, cells from affected BII1 had significantly more chromosomal breaks than cells from 
heterozygote BI2 (p = 5.49x10-7) or BII3 (p =  1.24x10-6; Fig. 3.9E). These studies indicate that 
both the c.1732+2T>C and the c.394C>T homozygous mutations in MCM9 impair repair of MMC 
induced chromosomal breakages. When comparing cells of the affected daughters from the two 
families to each other, BII1 (c.394C>T) appears to be more sensitive to chromosomal breakage at 
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50 nM (average breaks/cell = 1.6±0.9) when compared to AII4 (c.1732+2T>C; average breaks/cell 
= 0.6 ± 0.5; p = 0.001) or AII6 (c.1732+2T>C; average breaks/cell = 0.8 ± 0.5; p = 0.00039).  AII4 
and AII6 had significantly more breaks then BII1 at 150 nM (10.5 ± 2.1 vs. 8.1 ± 2.3 vs. 4.0 ± 1.1, 
respectively; AII4 vs. BII1, p = 7.5x10-6; AII6 vs. BII1, p =  
4.96x10-8). At the highest concentration of MMC, BII1 (average breaks/cell = 23.5 ± 6.6) had 
significantly more breaks/cell on average than AII6 (average breaks/cell = 14.79 ± 9.23; p = 
0.0051) but not AII4 (average breaks/cell = 24.1 ± 4.0; p = 0.81). Overall, the stop codon mutation 
(c.394C>T) appears to have a statistically greater effect on DNA damage repair in cells treated 
with MMC at 50 nM MMC then those cells with the splice site variant (c.1732+2T>C). However, 
at higher MMC concentrations cells of homozygous carriers fail to repair DNA damage as 
compared to heterozygous or wild type carriers. WES data analysis from affected sisters in either 
family did not reveal pathogenic variants in genes known to be associated with chromosomal 
instability and/or ovarian failure (Table 3.7).  
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Gene Associated Syndrome AII4 AII6 BII1 
ATM Ataxia-telangiectasia None None None 
BRCA1 Breast Cancer Benign SNP Benign SNP Likely Pathogenic SNP 
BRCA2 Fanconi Anemia, Wilms tumor, and cancers None None None 
BRIP1 Fanconi anemia, Breast Cancer None None None 
ERCC4 Fanconi anemia None None Benign SNP 
FANCA Fanconi anemia None Benign SNP Benign SNP 
FANCB Fanconi anemia Benign SNP None None 
FANCC Fanconi anemia None None Benign SNP 
FANCD2 Fanconi anemia None None None 
FANCE Fanconi anemia None None None 
FANCF Fanconi anemia None None None 
FANCM Fanconi anemia None None None 
FMR1 Fanconi anemia None None None 
HGPS Hutchinson-Gilford progeria None None None 
MCM8 Primary Amenorrhea, Endocrine Dysfunction None None None 
MLH1 Mismatch repair cancer syndrome None None None 
MLH3 Colorectal Cancer, Endometrial Cancer None None None 
MSH2 Mismatch repair cancer syndrome None None None 
MSH3 Endometrial carcinoma None Benign SNP None 
MSH6 Mismatch repair cancer syndrome None None None 
NBN Nijmegen breakage syndrome None None None 
NBS1 Nijmegen Breakage Syndrome None None None 
PALB2 Fanconi anemia None None None 
PHF9 Fanconi anemia None None None 
RAD50 Nijmegen breakage syndrome-like disorder None None Benign SNP 
RAD51C Fanconi anemia None None None 
SLX4 Fanconi anemia None None None 
TP53 Multiple Cancers None None None 
WRN Werner syndrome None None None 
XPC Xeroderma pigmentosum None None None 
XRCC9 Fanconi anemia None None None 
Table 3.7 WES Variants in Genes Known to Be Involved in Chromosomal Instability or Primary Amenorrhea, 
Families A and B. 
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3.1.2.3 Impairment of DNA Damage-Dependent Foci in Families A and C and Impairment 
of DNA Binding in Family C 
MCM8 and MCM9 containing complexes are known to form foci at sites of DNA damage (76). 
To determine if the c.1732+2T>C mutation affects the ability of MCM9 to form foci at sites of 
DNA damage, we generated an MCM9-GFP cDNA construct lacking exon 9 (c.1732+2T>C). 
After MMC exposure of cells expressing wild-type MCM9-GFP, GFP expression was observed 
primarily in the nucleus with an average of 20 ± 3 (SD) nuclear GFP foci/cell formed at sites of 
DNA damage (Fig. 3.10C, top). Interestingly, in mitomycin exposed cells expressing mutant 
MCM9-GFP, GFP signal was localized to the nucleus but foci could not be found at sites of DNA 
damage (Fig. 3.10C, bottom). These studies indicate that the MCM9 c.1732+2T>C pathogenic 
variant, lacking exon 9, inhibits MCM9 from being recruited to sites of DNA damage. 
In similar fashion, we generated a MCM8-GFP construct containing the 
c.446C>G/p.P149R mutation to determine if foci formation was affected. Cells were transfected
with the MCM8-GFP constructs and treated with 300 nM MMC to induce DNA damage. GFP 
expression was primarily nuclear, with an average of 14 ± 0.9 nuclear GFP foci/cell formed at sites 
of DNA damage in cells expressing wild-type MCM8-GFP (Fig. 3.10A, B). Significantly fewer 
nuclear GFP foci form, averaging 3.5 ± 0.2 foci/cell (p < 0.001; Fig. 3.10A, B) in cells expressing 
mutant MCM8-GFP.  The GFP fluorescence was more diffuse throughout the nucleus and the 
cytoplasm (Fig. 3.10A). These experiments show that the c.446C>G/p.P149R mutation inhibits 
MCM8 recruitment to sites of DNA damage.  
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Figure 3.10 MCM8 and MCM9 Mutations Disrupt Foci Formation and DNA Binding.  
(A) MCM8 c.446C>G (p.P149R) mutation inhibits MCM8 foci formation at sites of DNA damage. HEK293T cells 
were transfected with WT MCM8-GFP (WT) or mutant MCM8-GFP (p.P149R) and treated with 300 nM MMC for 6 
hours. Nuclei were counterstained with DAPI (blue). Nuclear foci formed in 293T cells expressing WT MCM8, but 
not in cells expressing mutant MCM8. Four independent experiments for transfection of MCM8-GFP (WT vs. 
p.P149R) coupled with DNA damage were performed. Representative confocal images are shown. (B) Twenty
representative cells per condition were quantified for the number of damage induced nuclear foci. A two-tailed T-test 
(assuming unequal variance) revealed a statistically significant difference (***, p<0.001) between the WT (14±0.9 
foci/cell) and c.446C>G (3.5±0.2 foci/cell) expressing cells. Error bars represent standard error. (C) MCM9 
1732+2T>C Disrupts Damage-Dependent Foci Formation. HEK293T cells were transfected with cDNA encoding 
wild-type MCM9-GFP (WT) or mutant MCM9-GFP which lacks exon 9 (1732+2T>C). Cells were treated with 300 
nM MMC for 6 hours. Nuclei were counterstained with DAPI (blue). Nuclear foci formed in 293T cells expressing 
wild-type MCM9, but not in cells expressing mutant MCM9. Representative confocal images taken with a 40x 
objective are shown. 
We also compared DNA binding of wild-type and mutant MCM8 protein. Wild-type and 
mutant MCM8 cDNAs were generated that correspond to the N-terminus of the protein that is 
predicted to bind DNA (nucleotides 1-1104; aa 1-368). We chose a random 46 nt single stranded 
DNA (ssDNA) since RAD51 is recruited to ssDNA ends at sites of damage and MCM8 is likely 
to bind at these sites (68). Wild-type MCM8 showed an increase in binding to ssDNA 
with concentration (Kd = 6.7+/- 0.8 µM; Fig. 3.11). Unlike wild type, mutant MCM8 does 
not saturate binding over the course of the titration, making calculation of a Kd difficult (Kd = not 
determined). These results show that the c.446C>G/p.P149R mutation impairs DNA binding 
ability at the N-terminus of MCM8.  
Figure 3.11 MCM8 c.446C>G (p.P149R) inhibits DNA binding by EMSA. 
(A) WT MCM8 or mutant MCM8 (p.P149R) protein was bound to a random 46 nt ssDNA oligonucleotide. Gels were 
imaged and quantification of the fraction of band shift was performed. Sample gels are shown in (B). Mutant MCM8 
(p.P149R, blue squares) showed a significant reduction in DNA binding affinity for ssDNA at each concentration 
when compared to WT MCM8 (WT, black circles). Each point is the average of three replicates. Error bars represent 
standard deviation. 
3.1.2.4 Evolutionary Comparison of the Selected MCM8 Region 
CLUSTAL Omega web site (http://www.ebi.ac.uk/Tools/msa/) was used to align the sequences 
from MCM8 proteins in human (Homo, NP_001268449. 1), mouse (Mus, NP_079952.2), frog 
(Xenopus, NP_001089437.1) and the predicted zebrafish sequence (Danio, XP_002665161.2).  
p.P149R is found at the evolutionary conserved Proline (highlighted in yellow, Fig. 3.7).
3.1.2.5 Homology Model of Human MCM8 and Crystallization Trials 
As a means of elucidating a model of the three-dimensional structure of human MCM8, archaeal 
SsoMCM (PDBID: 3F9V) was used as a template for threading the sequence of HsMCM8 using 
SWISS-PDB. The p.P149R mutation is located within a loop connecting two alpha-helices in the 
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A-domain which pack on top of the C-terminal domain (Fig. 3.12).  Mutation of p.P149R will 
most likely disrupt a turn within the A-domain.  
The crystal structure of Methanothermobacter thermautotrophicus MCM (mtMCM) has 
been solved and studied as a model for eukaryotic MCMs (62). Specifically, the mtMCM crystal 
structure provides insights into the bob-1 mutation in yeast (P62L) MCM5, which is homologous 
to MCM8 p.P149R. The MCM5 bob-1 mutation as a bypass suppressor to Cdc7/Dbf4 deletions 
(152). Cdc7/Dbf4 normally regulates entry into S-phase through phosphorylation of the MCM2-7 
complex, but the bob-1 mutation bypasses this requirement. Structural analysis of the homologous 
mutation in mtMCM was shown to weaken contacts in the N-terminal domain, making it more 
flexible, but it does not significantly affect DNA binding or ATPase activity in vitro (62, 153).  
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Figure 3.12 Homology model of human MCM8. 
Local and global sequence alignments were performed using ClustalW2 analysis 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi). The homology model of human MCM8 was creating by 
threading the adjusted alignment (WT or P149R) onto the structure of Sulfolobus solfataricus MCM (PDBID: 3F9V) 
(60) using SWISS-MODEL (154). P149R is located within a loop connecting two alpha-helices in the A-domain 
which pack on top of the C-domain. Proline 149 is circled by a black dashed line. NHP - N-terminal hairpin, WA- 
Walker A, WB - Walker B, S1 - Sensor 1, RF - Arginine finger, S2  - Sensor 2, WH - Winged helix. Colored domains 
correspond with linear protein diagram in Figure 3.1C. 
To obtain a more accurate representation of the MCM8 structure, we have performed 
crystallization trials with the purified N-terminal domain of MCM8 in collaboration with Andrea 
Berman, PhD and Roni Lahr.  Initial crystallization trials as well as optimization were performed 
with either MCM8(1-368) and MCM8(73-368). Initial MCM8(1-368) crystals became visible after 
1 hour (Fig. 3.13), and were screened using FR-E rotating anode and Saturn 944 CCD image plate 
detector. These MCM8(1-368) crystals contained protein but diffracted very poorly due to high 
solvent content or poor crystal packing. We addressed this issue by performing crystallization trials 
of MCM8(73-368). We designed the MCM8(73-368) truncation because of the lack of secondary 
structure predicted in the first 73 amino acids, predicted using the PSIPRED Protein Analysis 
Workbench (http://bioinf.cs.ucl.ac.uk/psipred/).  Unfortunately, only micro crystals grew in these 
trials.  Crystal macro and micro seeding using was also attempted, but did not result in enough 
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crystal growth to allow for diffraction. Crystallization of alternative protein truncations or variation 
in buffers and methods may yield the crystal structure of MCM8 in the future.  
Figure 3.13 MCM8(1-368) microcrystals.  
Crystals were grown in 25% PEG 8000, 100mM HEPES pH 7. Crystals were screened using FR-E rotating anode and 
Saturn 944 CCD image plate detector. 
3.1.2.6 DNA Binding Domain Mutation in MCM8 Impairs DNA Damage-Dependent Foci 
To extend our investigation of the ability of MCM8 to form damage-dependent nuclear foci, we 
investigated MCM8 p.E341K, the nonsynonymous SNP previously associated with age of natural 
menopause (81, 83-87). The p.E341K mutation is contained within the N-terminal hairpin of the 
DNA binding domain (Fig. 3.1) of MCM8 suggesting that this mutant may be defective in 
responding to DNA damage and binding DNA. We generated a MCM8-GFP construct containing 
the p.E341K mutation to determine if foci formation was affected. Cells were transfected with the 
MCM8-GFP constructs and treated with 300 nM MMC to induce DNA damage. As described 
previously, GFP expression was primarily nuclear, with an average of 14 ± 0.9 nuclear GFP 
foci/cell formed at sites of DNA damage in cells expressing wild-type MCM8-GFP (Fig. 3.14A, 
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B). Significantly fewer nuclear GFP foci form, averaging 4.7 ± 0.2 foci/cell (p < 0.001; Fig. 3.14A, 
B) in cells expressing mutant MCM8-GFP. The GFP
Figure 3.14 MCM8 p.E341K disrupts damage-dependent foci formation. 
(A) MCM8 p.E341K inhibits MCM8 foci formation at sites of DNA damage. HEK293T cells were transfected with 
WT MCM8-GFP (WT) or mutant MCM8-GFP (p.E341K) and treated with 300 nM MMC for 6 hours. Nuclei were 
counterstained with DAPI (blue). Nuclear foci formed in 293T cells expressing WT MCM8, but not in cells expressing 
mutant MCM8. Four independent experiments for transfection of MCM8-GFP (WT vs. p.E341K) coupled with DNA 
damage were performed. Representative confocal images are shown. (B) Twenty representative cells per condition 
were quantified for the number of damage induced nuclear foci. A two-tailed T-test (assuming unequal variance) 
revealed a statistically significant difference (***, p<0.001) between the WT (14±0.9 foci/cell) and p.E341K (4.7±0.2 
foci/cell) expressing cells. Error bars represent standard error. Representative confocal images taken with a 40x 
objective are shown. 
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fluorescence was more diffuse throughout the nucleus (Fig. 3.14A). These experiments show that 
the p.E341K mutation inhibits MCM8 recruitment to sites of DNA damage in a manner similar to 
the pathogenic MCM8 mutant p.P149R. 
3.1.3 Conclusion 
We used homozygosity mapping, SNP Arrays and WES in a consanguineous family to identify a 
homozygous recessive pathogenic variants in MCM8 (c.446C>G) and MCM9 (c.1732+2T>C and 
c.394C>T). These three variants were identified as causes of a novel syndrome in humans
characterized by ovarian insufficiency, hypothyroidism, and genomic instability in somatic cells. 
The MCM8 p.P149R substitution occurs in a highly conserved region of MCM8 predicted to bind 
DNA. Individuals homozygous for this variant show high numbers of chromosomal breaks when 
exposed to MMC and the p.P149R mutation inhibits MCM8 foci formation at sites of DNA 
damage. MCM8 p.P149R mutant protein shows impaired binding to DNA and likely prevents 
repair at these sites. Heterozygote sisters and their mother have unremarkable medical histories to 
date. This is consistent with the unaffected carrier state. There is no known family history of 
cancers. Future follow-up and phenotyping of additional individuals with MCM8 variants will be 
of great importance to understand their predisposition to cancer. Given the consanguineous nature 
of the family, we cannot rule out a possibility that other genes contribute to the observed clinical 
phenotype.   
The c.1732+2T>C pathogenic variant converted a conserved splice donor site GT to a GC, 
that resulted in aberrant splicing. The c.394C>T pathogenic variant introduces a premature stop 
codon in exon 2 of MCM9, at amino acid 132, in a protein that contains 1143 amino acids, and is 
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predicted to generate a truncated protein that lacks half of the DNA binding domain and all of the 
ATPase domain. We also showed that cells containing the c.1732+2T>C and c.394C>T variants 
are impaired in their ability to repair DNA damage likely due to the inability of MCM9 to be 
recruited to sites of DNA damage. Affected women in both families showed higher number of 
chromosomal breaks as compared to heterozygotes or wild type controls. A similar effect is 
observed in cells homozygous for MCM8 p.P149R (155). 
Minichromosome maintenance proteins, MCM2-7 have been implicated in DNA 
replication elongation and pre-replication complex formation (145). MCM8 and MCM9 are the 
most recently discovered members of the minichromosome maintenance protein family and by 
association with other MCMs, were initially implicated in DNA replication (69). Unexpectedly, 
MCM8 and MCM9 deficient mice showed a phenotype primarily restricted to the germline with 
infertility and small gonads (74). In addition, somatic cells exhibited growth defects and 
chromosomal instability (74). MCM8 and MCM9 are therefore novel regulators of germ cell 
survival, rapidly induced and recruited to DNA damage sites, co-regulate each other’s stability, 
and promote RAD51 recruitment to the chromatin . The mechanisms of their action, induction, 
and regulation in homologous recombination remain poorly understood. The phenotype of the 
three affected individuals from two independent families is very similar to what has been described 
in mouse knockouts.  
The mechanism of MCM8 and MCM9 action in the maintenance of the germline remains 
to be elucidated. MCM8/MCM9 complex is likely required for the resolution of double stranded 
DNA breaks that occur during homologous recombination between homologous chromosomes in 
pachytene of meiosis I (72). Failure to resolve breaks will lead to oocyte death and thus very small 
or absent ovaries in women homozygous for these mutations. A number of mouse mutants lacking 
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genes involved in meiosis and DNA repair, such as DMC1 and Msh5, lose oocytes rapidly in part 
due to their inability to process double stranded DNA breaks (156, 157). Indeed, mutations in 
DMC1 and Msh5 were identified in women with POF (158). Double stranded DNA break repair 
genes have been implicated in the on the onset of menopause by genome wide association studies, 
including a SNP in MCM8 (rs16991615) (81, 83-87). Although no association has been identified 
between menopause and MCM9, the close physical interdependence of these two proteins shows 
the importance of this novel pathway in a spectrum of ovarian functions from gonadal development 
to menopause.  
Genomic instability syndromes, such as Fanconi anemia (FANCA [MIM 227650]) (159), 
can associate with short stature, hypogonadism, and multiple endocrine dysfunctions (160).  The 
mechanism of how genomic instability contributes to endocrinopathies has not been elucidated 
and is likely linked to complex regulatory networks in the hypothalamic-pituitary-endocrine axes 
of the body (160). Heterozygote sisters and mothers had unremarkable medical histories to date. 
The mothers of both families entered menarche between the ages of 13 and 15 years and did not 
develop POF. There is no known family history of cancers, however affected individuals may have 
an increased risk, particularly if exposed to DNA damage agents. Affected patients presented with 
hypergonadotropic hypogonadism, primary amenhorrea, and short stature. Future follow-up and 
phenotyping of additional individuals with MCM9 variants will be of great importance to 
understand their predisposition to other disorders including endocrine dysfunction and cancer 
predisposition.  
A role for MCM8 in gonadal development and maintenance has been confirmed since the 
publication of these findings. Two novel homozygous mutations in MCM8: a splice site mutation 
(c.1954-1G>A) and a frameshift mutation (c.1469-1470insTA) were identified as the genetic 
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causes of primary amenorrhea in females and small testes and azoospermia in males (82). The two 
mutations are predicted to produce truncated, non-functional proteins. Quantitative analysis of 
MCM8 transcript revealed low abundance of the aberrant transcripts in affected cells, compared 
with the abundance of wild-type MCM8 transcript in unaffected cells. Similar to the findings in 
our families, it was found that both of these MCM8 mutations lead to difficulty in repairing 
chromosomal breaks induced by MMC treatment (82).  
MCM8 p.E341K is highly associated with the age of natural menopause, and meta-analysis 
of menopause GWAS studies strongly implicates DNA repair pathways (81, 83-87). While our 
findings show the importance of this residue for the response of MCM8 to DNA damage, the 
functional relevance of MCM8 p.E341K in reproductive senescence has not yet been elucidated. 
Our study shows that MCM8, when inherited in Mendelian fashion, is essential for normal gonadal 
development. Future studies and follow-up on these and additional individuals will be necessary 
to define the spectrum of human phenotypes associated with MCM8 variants. The role of the novel 
MCM8/MCM9 pathway in women with idiopathic POF needs to be explored further.      
3.1.4 Experimental 
3.1.4.1 DNA Mapping and Whole Exome Sequencing 
DNA copy number analysis and homozygosity mapping was performed using a 180K comparative 
genomic hybridization (CGH) + single nucleotide polymorphism (SNP) oligonucleotide array 
(SurePrint G3 ISCA design CGH+SNP, Agilent, Santa Clara, CA).   
Whole exome sequencing was performed. Exons and splice sites were captured using the 
Agilent SureSelectXT Human Exon v4+UTRs Kit (Agilent, Santa Clara, CA) and 2x100 bp 
paired-end WES was performed on an Illumina HiSeq 2500 (Illumina Inc., San Diego, CA, USA). 
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Quality metrics for sequencing are shown in Table 3.8. Reads were prepared for analysis using 
Cutadapt version 1.2.1 to remove the adapters and the Fastx Toolkit 0.0.13.2 to trim the first 5 bp 
at 5' end of reads. Data was aligned to NCBI37/hg19 using BWA version 0.7.3a MEM (Maximum 
Exactly Match) (161, 162). Alignment statistics are presented in Tables 3.8 and 3.9. Local 
realignment around insertions and deletions, reads base quality recalibration, and variant calling 
were conducted using GATK Tool Kits version 2.6-5. GATK HaplotypeCaller (HC) was used to 
call variants. Filtering of variants is described in Table 3.10. The number of family members and 
availability of unaffected siblings enhanced the ability to filter gene variants that did not match an 
autosomal recessive inheritance model. 
Samp
le ID 
Samples 
in Flow 
Cell 
Lane 
Yield 
(Mbases) 
Number of 
Reads 
% of 
raw 
clusters 
per lane 
% of 
Perfect 
Index 
Reads 
% of One 
Mismatch 
Reads 
(Index) 
% of >= 
Q30 Bases 
(PF) 
Mean 
Quality 
Score 
(PF) 
AI1 1 40,014 400,142,260 99.31 97.87 2.13 89.32 34.95 
AI2 1 40,103 401,028,406 96.61 95.91 4.09 88.38 34.62 
AII1 3 10,564 105,639,628 25.43 99.29 0.71 88.14 34.58 
AII2 1 38,942 389,418,144 99.25 98.06 1.94 89.94 35.10 
AII3 2 21,150 211,502,536 53.01 98.52 1.48 89.73 35.06 
AII4 1 37,010 370,102,596 99.20 99.11 0.89 90.08 35.18 
AII5 1 37,489 374,888,092 99.37 99.52 0.48 90.93 35.41 
AII6 1 39,231 392,306,596 99.19 98.50 1.50 89.47 34.99 
AII7 2 18,405 184,053,748 46.13 99.03 0.97 89.80 35.09 
BI1 2 16,244 162,437,184 41.25 79.91 20.09 86.17 33.95 
BI2 2 10,532 105,319,862 26.74 79.86 20.14 86.33 33.98 
BII1 2 16,802 168,018,024 42.56 77.08 22.92 84.58 33.44 
BII3 2 18,121 181,214,362 45.91 77.23 22.77 84.07 33.29 
Table 3.8 Quality Metrics for Sequencing by Sample, Families A and B 
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Sample 
ID 
Reads Aligned to the 
Exome 
Average 
Coverage Across 
Exome (reads) 
Average Coverage 
of Called Variants 
(reads) 
AI1 351,637,889 324 130 
AI2 356,961,485 329 150 
AII1 90,981,936 84 101 
AII2 344,391,857 317 128 
AII3 181,142,719 167 117 
AII4 329,790,954 304 131 
AII5 330,827,415 305 154 
AII6 352,234,023 324 158 
AII7 166,247,481 153 131 
BI1 132,290,201 236 121 
BI2 84,124,803 153 105 
BII1 126,805,441 240 125 
BII3 145,614,552 264 124 
Table 3.9 Whole Exome Sequencing Alignment Statistics, Families A and B 
MCM9 early stop codon mutation was identified using the same methodology described 
above. Primers to bracket c.394C>T variant (chr6:119,245,033-119,245,256, NCBI37/hg19) were 
5’ – GCC TGA GAG GCA AGT GAA TTT AG – 3’ and 5’ – TAC CTA AAA CCA AGG ATG 
TGG GA – 3’. The premature stop codon is assumed to result in loss of functional protein and 
therefore inhibit the function of MCM9. 
Family A Family B 
Total Variants Called in the Family 36,908 38,060 
Application of GATK Quality Filters 36,056 37,430 
Variants in Exons or Splice Sites 25,512 26,369 
Nonsynonymous Variants 12,048 12,560 
Remove Known Polymorphic Genes from NIH 
Recommendations 
10,835 11,141 
Variants with a Minor Allele Frequency <5% 1,765 1,743 
Coverage >8 1,640 1,676 
Homozygous Recessive 3 19 
Table 3.10 Whole Exome Sequencing Variant Filtration, Families A and B 
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3.1.4.2 SNP Arrays and Whole Exome Sequencing to Identify MCM8 c.446C>G 
Regions of homozygosity within the family were mapped using Affymetrix GeneChip Human 
Mapping 250K Nsp array (Affymetrix). Data was deposited in the Gene Expression Omnibus 
(Accession Number GSE56043). Exons and splice sites were captured using the Agilent Haloplex 
All Exon Kit and WES was performed on an Illumina HiSeq 2500. Raw data were deposited in 
the Sequencing Reads Archive (ID number SRP046742). Sanger sequencing was used to confirm 
WES discovered variants and to evaluate 200 fertile controls for putative damaging variants.  
3.1.4.3 Verification of MCM9 c.1732+2T>C Splice Site Mutation 
The MCM9 c.1732+2T>C variant was confirmed by Sanger Sequencing (Fig. 3.6A). Verification 
of the MCM9 c.1732+2T>C variant was completed via PCR amplification of the region 
surrounding the variant using KAPA HiFi Taq Polymerase according to manufacturer’s 
instructions. Primers to bracket the c.1732+2T>C variant (chr6:119,148,847-119,149,165, 
NCBI37/hg19) were 5’ – TCT AGG AGG TCC CGA GAT GG -3’ and 5’ – CAA AGG CAG 
AGT GAT TGC CG – 3’. PCR products were then sent to Beckman Coulter Genomics (Danvers, 
MA) for sequencing. Results were analyzed using Sequencher (Gene Codes Corporation, Ann 
Arbor, MI USA). Sample chromatograms are shown in Fig. 3.6A (bottom).  A control population 
of Caucasian women, who had at least one live birth, was recruited at Magee-Womens Hospital. 
Informed written consent and samples were obtained and subsequently de-identified at the time of 
recruitment. The study was approved by the Institutional Review Board of the University of 
Pittsburgh. The MCM9 c.1732+2T>C mutation was not present in the 200 fertile women from this 
cohort. The exon 9 splice donor site is conserved at the nucleotide level across species including 
mouse, xenopus, and zebrafish.  
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3.1.4.4 Identification of mRNA Isoforms Resulting from MCM9 c. 1732+2T>C Mutation 
We isolated mRNA from Epstein-Barr virus transformed lymphoblastoid cell lines using Trizol 
(Invitrogen) from unaffected mother AI2 (heterozygous), and affected daughter AII6 (homozygous 
for the mutation), and converted it to cDNA using Super Script III First Strand Synthesis kit 
(Invitrogen). To amplify mRNA isoforms, we used KAPA HiFi Hotstart PCR Kit with dNTPs 
(KAPA Biosystems). 
3.1.4.5 Foci Formation Assays 
Human wild-type MCM9 was cloned into pEGFPc2 (Clontech) in frame with the N-terminal GFP 
tag using XhoI and SalI. pEGFPc2-MCM9 c.1732+2T>C was generated by Quikchange 
introducing an SphI  site for screening. Human wild-type MCM8 was cloned into pEGFPc2 
(Clontech) in frame with the N-terminal GFP tag using BglII and BamHI. pEGFPc2-MCM8 
p.P149R was generated by Quikchange and KAPA HiFi polymerase introducing an NruI site for
screening. pEGFPc2-MCM8 p.E341K was generated by Quikchange and KAPA HiFi polymerase 
introducing a BamHI site for screening. Human embryonic skin keratinocytes (293T cells) were 
seeded onto 12-cm glass coverslips coated in poly-L-lysine and cultured under standard conditions. 
Transient transfection of either wild-type MCM9-GFP or mutant MCM9-GFP (c.1732+2T>C) into 
293T cells was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
directions and cells were exposed to 300 nM mitomycin C (MMC) for 6 hours the following day 
to induce DNA damage.  Coverslips were rinsed twice in PBS, fixed with 3% paraformaldehyde 
for 15 minutes, and incubated in PBS with 20% sodium dodecyl sulfate and 10% Triton-X-100 for 
15 minutes.  Coverslips were mounted using Fluoroshield + DAPI (Sigma) and imaged using an 
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Olympus Fluoview 500 or Olympus Provis AX70 confocal microscope. GFP foci were counted in 
15 cells per experiment. 
3.1.4.6 Functional Analysis of Chromosomal Instability 
Peripheral lymphocytes from unaffected (IV-3, III-2; Fig. 3.8A-B and AII2, BI2, and BII3; Fig. 
3.9A) and affected (IV-1; Fig. 3.8C and AII4, AII6, and BII1; Fig. 3.8B,C) family members were 
stimulated with phytohaemagglutinin (PHA) and cultured in the presence of MMC as described 
previously (150). The control for these studies was an unrelated female individual whose cells 
were used as a baseline for comparison in both families. Briefly, cells were cultured in the presence 
of MMC at concentrations of 0 nM, 50 nM, 150 nM, or 300 nM. Cells were harvested after 72 
hours of incubation at 37°C. At least ten metaphase spreads per sample were evaluated for 
chromosome aberrations and breaks (Fig. 3.8 and Table 3.11). 
Sample MCM9 Genotype 
Mitomycin C Concentration 
0 nM 50 nM 150 nM 300 nM 
Control 0±0 0.4±0.5 0.5±0.5 0.8±0.4 
Family A – c. 1732+2T>C 
AII2 WT/MT 0±0 0.2±0.4 0.6±0.5 0.8±0.6 
AII4 MT/MT 0.1±0.3 0.6±0.5 10.5±2.1 24.1±4.0 
AII6 MT/MT 0.2±0.4 0.8±0.5 8.1±2.3 14.8±9.2 
Family B – c.C394T 
BI2 WT/MT 0.2±0.4 0.1±0.3 0.3±0.5 1.9±2.2 
BII1 MT/MT 0.1±0.4 1.6±0.9 3.9±1.2 23.5±6.6 
BII3 WT/WT 0.2±0.4 0.2±0.4 0.4±0.6 1.2±1.8 
Table 3.11 Average number of Chromosomal Breaks Per Cell After MMC Treatment, Families A and B 
3.1.4.7 DNA Binding Assay 
We generated wild-type and mutant MCM8 cDNAs corresponding to the N-terminus of the protein 
that is predicted to bind DNA, and compared their ability to bind DNA. The wild type MCM8 
cDNA fragment that encodes N-terminus (nucleotides 1-1104; amino acids 1-368) was amplified 
from HeLa cell cDNA with Accuzyme polymerase (Bioline; F: 5’-CAC CGG ATT CAT GAA 
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TGG AGA GTA TAG AGG CAG; R: 5’- ATT ATG CAT CTA CTG TCC TTT GCT ATT ACT 
AAT AGA ATT TG), and subcloned into a pET30a expression vector (EMD Chemicals) using 
BamHI and NotI to allow for expression of an N-terminal 6XHis tag used in purification. The 
c.446C>G mutation was generated using a standard Quikchange protocol with KAPA HiFi DNA
polymerase. MCM8 wild-type and mutant proteins were induced in BL21(DE3) Rosetta 2 cells 
with IPTG (0.1 mM; 16 hours at 15°C). Cells were lysed and sonicated (buffer: 20 mM sodium 
phosphate buffer [pH 7.5], 300 mM NaCl, 10 mM imidazole, 10 mM β-mercaptoethanol, and 
lysozyme). Soluble protein was purified using a nickel column (Thermo Fisher), washed with 100 
mM NaCl, eluted with 250 mM imidazole, and further purified using an AKTA Prime FPLC 
system with a HiTrap heparin column (GE Healthcare). Final cleanup and sizing was performed 
with a Superdex 200 26/60 column (GE Healthcare). The extinction coefficient of MCM8 1-368 
was determined to be 40,380 M-1 cm-1.  Electrophoretic mobility shift assays (EMSAs) were 
performed. As the affinity of MCM8 to DNA remains unknown, we chose a random 46 nucleotide 
long single stranded DNA (ssDNA; 5’-CGA TGA GAG CGA GTC GCA TGG TAT CCC GTA 
AAT TGG GAT GCT TAG GCT TA – 3’), as RAD51 is recruited to ssDNA ends at sites of 
damage and MCM8 is likely to bind at these sites (68). EMSAs were performed in a 15 µl reaction 
volume containing 20 mM sodium phosphate buffer (pH 7.5), 100 mM NaCl, 20 mM β-
mercaptoethanol and 5 nM DNA probe labeled at the 5′-end using a standard polynucleotide kinase 
reaction and 32P-γ-ATP, and the indicated amount of MCM8. Binding reactions were allowed to 
equilibrate for 5 min followed by directly loading onto a 6% polyacrylamide/TBE gel. Gels were 
run for 20 minutes at 13 volts cm−1 followed by imaging using a Storm phosphorimager (GE 
Healthscience). Quantification of the fraction of band shift was performed using the ImageQuant 
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software (v5.0). Data were fit using Kaleidagraph (Synergy) to a single site binding model defined 
by ΔF[MCM8]/Kd + [MCM8] where F is the fraction bound and Kd is the dissociation constant.  
3.1.4.8 Homology Model of Human MCM8  
Modeling of MCM8 and the identification of the p.P149R substitution was created using Swiss-PDB after 
threading the sequence alignment onto the structure of Sulfolobus solfataricus MCM (PDBID:3F9V).   
3.1.4.9 Crystallization of MCM8 N-Terminal Domain 
Initial crystallization trials were performed by hanging drop vapor diffusion with the 12 most 
common crystallization buffer conditions at 2-6 mg/ml and 1:1, 1:2, 2:1 protein to mother liquor 
ratio. Crystals began to become visible after 1 hr, both at 4° C and room temperature. After growth, 
these initial crystals were screened using vapor drop vapor diffusion with a 1:1 ratio of protein at 
3 mg/ml in a random sparse matrix screen (Wizard II Emerald Bio Systems). Crystals grew in two 
conditions: 25% PEG 3350, 100mM Tris pH 8.5, 200 mM LiSO4 and 25% PEG 8000, 100 mM 
HEPES pH 7. Crystals were optimized at 17% PEG 3350, 100 mM Tris pH 8.5, 200 mM LiSO4 
and grew to 0.5 to 1 um final at 4 degrees. Crystals equilibrated to 30% PEG3350, 100 mM Tris 
8.5, 200 mM LiS04 to cryoprotect and flash frozen in liquid nitrogen. Crystals were screened using 
FR-E rotating anode and Saturn 944 CCD image plate detector.  
For crystallization of MCM8(73-368), 1:1 ratio of protein at 5, 20, 25 and 30 mg/mL was 
screened in random sparse matric screen using hanging drop diffusion (Wizard I& II Emerald Bio 
systems, JCSG plus core suite)   
Crystal macro and micro seeding was performed using these crystals. Moved single crystal 
into 15% PEG 3350, 100mM Tris pH 8.5, 200 mM LiSO4 for 2, 5, or 10 minutes and then moved 
into stabilization conditions 16-25% PEG 3350, 100 mM Tris pH 8.5, 200 mM LiSO4. 
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4.0  TOWARDS THE ACTIVITY AND FUNCTION OF MCM9 MOTIFS 
4.1 MCM9 C-TERMINUS IS ESSENTIAL FOR RESPONSE TO DNA DAMAGE 
4.1.1 Research Design 
MCM8 and MCM9 bear significant sequence homology and form a stable nuclear complex, 
demonstrated in co-immunoprecipitation studies (67, 68). While both proteins were initially 
implicated in normal DNA replication (45, 69, 70), MCM8 and MCM9 knockout mice are viable 
but encounter difficulties in germ-line stem-cell maintenance and homologous recombination 
(HR) (74, 75). Depletion of MCM8 or MCM9 results in genomic instabilities, sex-specific tumor 
development, and sterility and the MCM8-9 complex participates in preventing or repairing DNA 
double strand breaks (DSBs) (74, 76). An interaction between Rad51, a key factor in HR and 
MCM8-9 forms the basis of this involvement in HR. The MCM8-9 complex interacts with Rad51 
in cell extract, shown through co-IPs and in live cells, MCM8 and MCM9 form foci at sites of 
DNA damage that co-localize with Rad51 (68, 74, 76, 163). MCM9-null mouse embryonic 
fibroblasts (MEFs) are defective in HR and impaired in their ability to recruit Rad51 to sites of 
DNA damage (68).  
MCM9L contains an extended C-terminus that does not possess homology to other 
members of the MCM family or to any other protein domain that we can identify (Fig. 1.2). 
Therefore, we set out to determine the functional significance of the extended MCM9 C-terminus. 
We have identified and validated specific motifs within the C-terminus that are responsible for 
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nuclear import as well as interactions with DNA damage foci. We predict that the role of the 
MCM9 C-terminus is to localize both MCM8 and MCM9 to the nucleus and interact with 
homologous recombination proteins during double strand break repair.  
4.1.2 Results 
4.1.2.1 MCM9M Is Cytoplasmic and MCM9Cterm Imports to Nucleus But Does not Form 
Damage-Dependent Nuclear Foci  
To investigate the role of the unique C-terminus of MCM9L in the response to DNA damage, we 
reproduced previously reported MCM9L foci (76) and observed the response of MCM9M and 
MCM9Cterm to MMC treatment. MCM9Cterm contains only amino acids 608-1143, excluding the 
AAA+ core domain of the protein, which is predicted to provide the basis of the protein’s 
enzymatic function.  
We transiently expressed pEGFPc2-MCM9L in 293T cells, treated cells with the 
crosslinking agent mitomycin C (MMC) to form nuclear GFP-MCM9L foci that were visualized 
with confocal microscopy (Fig. 4.2).  In the absence of DNA damage, MCM9L is exclusively 
nuclear. Interestingly, GFP-MCM9L also forms foci in the absence of damage, but the number of 
foci increases significantly in number (> 5-fold) upon exposure to MMC (164).  
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Figure 4.1 Formation of MCM9 foci at sites of DNA double-strand breaks.  
293T cells were transfected with GFP-tagged MCM9 constructs and exposed to 300 nM MMC for 6 hrs to induce 
formation of DNA double-strand breaks. Nuclei were stained with DAPI and nuclear foci were visualized with 
confocal microscopy. While MCM9L readily forms nuclear damage-dependent foci, MCM9M is localized to the 
cytoplasm and MCM9Cterm is nuclear, but does not form damage-dependent foci. 
Transiently transfected pEGFPc2-MCM9M is mainly cytoplasmic, suggesting that the 
unique C-terminus of the protein is important for nuclear import. MCM9M does not form damage-
induced foci, and there is no nuclear localization of the isoform. This finding suggests that the C-
terminus of MCM9 contains a motif necessary for nuclear localization.  
A transiently expressed GFP-tagged version of the C-terminus of MCM9 (aa608-1143, 
Fig. 4.3B) localizes to the nucleus of the cell but does not form foci in response to double-strand 
breaks formed by exposure to MMC (Fig. 4.1). This finding, together with the observation that 
MCM9M does not enter the nucleus supports the importance of the C-terminus for nuclear import. 
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The inability of this construct to form damage-induced foci supports the importance of the AAA+ 
core domain for the response of MCM9 to DNA damage. As the C-terminal tail alone (aa 608-
1143) is insufficient to form foci, we conclude that the AAA+ core domain is also necessary for 
damage-dependent foci formation. 
4.1.2.2 MCM9 NLS- Disrupts Nuclear Localization 
Based on the results shown in Fig. 4.1, we searched for a putative nuclear localization 
signal in the C-terminus of MCM9 using the NLS prediction tool: nls-mapper.iab.keio.ac.jp/. The 
nuclear localization signal (NLS) is a series of positively charged lysines or arginines on the 
surface of the protein that interact with the α-subunit of the cytosolic receptor importin (165, 166). 
The β subunit of importin binds to the nuclear pore and allows for nuclear import (166, 167). Using 
the NLS prediction tool, we identified amino acids 891PKRK as a putative NLS. MCM8 is devoid 
of an NLS, and we expect that complexation with MCM9 allows MCM8 to enter the nucleus. We 
cloned MCM9 NLS-, containing the mutation in the putative NLS motif (MCM9 c.891PKRK-
GKDD) into pEGFPc2. This mutation was designed to replace several amino acid residues that 
are positively charged at physiological pH (arginine and lysine) with negatively charged residues 
(aspartic acid) predicted to disrupt nuclear import (167).   
A transiently expressed GFP-tagged version of MCM9 NLS- is exclusively found in the 
cytoplasm and does not form foci in response to DNA double-strand breaks (Fig. 4.2). The 
cytoplasmic localization of this construct supports the importance of the NLS for nuclear import. 
The localization of MCM9 NLS- is similar to that of MCM9M, confirming the importance of the 
C-terminal extension and the NLS motif in particular for nuclear import and damage-dependent 
foci formation.  
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Figure 4.2 MCM9 NLS- disrupts nuclear import.  
293T cells were transfected with GFP-tagged versions of mutated or wild type MCM9 and exposed to 300 nM MMC 
for 6 hrs to induce formation of DNA double-strand breaks. Nuclei were stained with DAPI and nuclear foci were 
visualized with confocal microscopy. While wild type MCM9 readily forms nuclear foci at sites of DNA damage, 
MCM9 NLS- does not localize to the nucleus. 
4.1.2.3 MCM9 BRCv- Disrupts Damage Induced Foci Formation 
BRCA2 interacts with Rad51 through a series of 8 conserved BRC motifs, encoded in exon 11 of 
the human BRCA2 gene (102, 103). These motifs are conserved in all mammalian BRCA2 proteins 
that have been sequenced (103). Yeast two-hybrid searches using various segments of the BRCA2 
gene as “bait” reveal that the interaction between Rad51 and BRCA2 arises in the BRC motifs 
(102). Each BRCA2 motif contains a 59-residue minimal region which forms the basis of the 
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Rad51 interaction. Two BRC motifs with an intervening linker region have been identified in the 
RecQl5 helicase and have been shown to be necessary for binding Rad51 (104). This domain, 
containing the two BRC motifs and linker region is considered a BRC variant (BRCv) motif. Co-
IPs between RecQl5 truncations and Rad51 reveal that this region is essential for Rad51 interaction 
(104). D-loop formation assays including purified truncations of RecQl5 and Rad51 have provided 
further evidence of the in vitro role of the BRCv motif forming an interaction with Rad51 (104). 
In vivo assays have also supported the function of the BRCv, such as sister chromatid exchange 
(SCE) assays which demonstrate that the BRCv motif of RecQl5 is sufficient to rescue SCE 
frequency in RecQl5-/- cells (104). Further, camptothecin resistance is restored by the BRCv motif 
of RecQl5 in RecQl5-/- cells (104). We have identified a BRCv motif in the C-terminus of MCM9 
that is homologous to the RecQl5 BRCv repeat motifs (Fig. 4.3) (104). We cloned MCM9 BRCv-
, in which two residues homologous to key Rad51-interacting residues in RecQl5, are mutated 
(FR687-8AA) (104). The damage-dependent cellular localization of this construct was observed.
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Figure 4.3 MCM9 BRCv and NLS motifs.  
(A) Alignment of the MCM9 BRCv motif with the 8 BRC motifs in BRCA2 and the one BRCv motif in RECQL5. 
(B) Location of BRCv and NLS motifs in MCM9 linear sequence. Both motifs are present in MCM9L and MCM9Cterm, 
but not in MCM9M. 
MCM9 BRCv- disrupts the BRCv motif which we propose to interact with Rad51 based on 
its homology to the RIP in BRCA2. A transiently transfected GFP-tagged version of this mutant 
is nuclear in damaged and undamaged cells, but does not form damage-induced foci (Fig. 4.4). 
This finding supports the importance of the BRCv motif for the response and localization of 
MCM9 to DNA damage.  
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Figure 4.4 MCM9 BRCv- disrupts damage-dependent foci formation.  
293T cells were transfected with GFP-tagged versions of mutant BRCv- MCM9 and exposed to 300 nM MMC for 6 
hrs to induce formation of DNA double-strand breaks. Nuclei were stained with DAPI and nuclear foci were visualized 
with confocal microscopy. While wild type MCM9 readily forms damage-dependent nuclear foci, MCM9 BRCv- 
localizes to the nucleus but does not form nuclear foci. 
4.1.3 Conclusion 
We have characterized multiple isoforms of MCM9 (MCM9L and MCM9M), a truncation 
(MCM9Cterm) and mutated versions of the protein (MCM9 NLS- and MCM9 BRCv-). In our 
analysis, we have determined the essential domains and motifs of MCM9 for nuclear import and 
DNA damage-dependent foci formation exist in the extended C-terminus. Our observations reveal 
that nuclear localization requires the NLS motif (891PKRK) and DNA damage-induced foci 
formation depends on the AAA+ domain and the BRCv- motif (FR687-688). While WT MCM9L 
readily forms damage-induced foci, MCM9M and MCM9 891PKRK-GKDD do not enter the 
nucleus, and MCM9Cterm and MCM9 FR687-688AA enter the nucleus but do not form foci. We 
would expect that the absence of a NLS in MCM8 would dictate that an MCM8/9 complex is 
imported to the nucleus through the NLS sequence in MCM9. The role of the BRCv motif in 
MCM9 will require further study to validate that the specific target is in fact Rad51 and that its 
importance is required for efficient DNA double strand break repair.  
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4.1.4 Experimental 
4.1.4.1 Transfections and Foci Formation Assays 
Human skin keratinocyte (293T) cells were seeded onto 12-cm glass coverslips coated in poly-L-
lysine and cultured in Dulbecco's Modified Eagle Medium supplemented with 4.5 g/L D-glucose, 
4.5 g/L l-glutamine, 4.5 g/L sodium pyruvate and 10% fetal bovine serum in a humidified 5% CO2 
incubator at 37°C.  Human wild-type MCM9L, MCM9M and MCM9Cterm were each cloned into 
pEGFPc2 (Clontech) in frame with the N-terminal GFP tag using SalI and XhoI. pEGFPc2-MCM9 
FR687-688AA was generated by Quikchange and KAPA HiFi polymerase introducing an AatII 
site for screening and pEGFPc2-MCM9 891PKRK-GKDD was generated similarly, introducing 
a BspEI site for screening. Transient transfection of plasmids in 293T cells was performed using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s directions. Cells were incubated 
with transfection mixture overnight, before adding 300 nM mitomycin C for 6 hours.  Coverslips 
were rinsed twice in PBS, incubated in PBS supplemented with 3% paraformaldehyde for 15 
minutes, and then incubated in PBS supplemented with 20% sodium dodecyl sulfate and 10% 
Triton-X-100 for 15 minutes.  Coverslips were mounted using Fluoroshield + DAPI (Sigma) and 
imaged using an Olympus Fluoview 500 confocal microscope.  
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5.0  MCM8 C.446C>G/P.P149R MUTATION CAUSES SENSITIVITY TO MMC BUT 
NOT TO PARP INHIBITORS 
5.1.1 Research Design 
When PARP-1 is inhibited, replication forks collapse at single-strand DNA interruptions and 
homologous recombination (HR) is triggered to repair the DNA breaks (114, 115). Cells deficient 
in HR proteins are thus highly sensitive to PARP inhibitors. PARP-1 does not directly catalyze 
HR, but its inhibition leads to accumulation of unrepaired SSBs, which become DSBs after one 
round of replication (168). Because of the initiation of HR in the absence of functional PARP-1, 
cells deficient in HR proteins are acutely sensitive to PARP inhibitors. This heightened 
susceptibility has been demonstrated in BRCA2-mutated or deficient tumor cells(115), PTEN-
deficient tumor cells (116) and PTEN-mutated cells (117). Knowing that MCM8 and MCM9 are 
important for Rad51 recruitment to sites of DNA damage, we investigated the synthetic lethal 
effect of MMC (Fig. 5.1) with either of the PARP inhibitors BMN673 or ABT-888 (Fig. 5.1) in 
cells either homozygous or heterozygous for MCM8 c.446C>G/p.P149R, in patients presenting 
with premature ovarian failure (discussed in further detail in Section 3.1.2.3).   
We first assessed the cytotoxicity of MMC and BMN673 individually, before determining 
their synergistic effect. Cells homozygous for MCM8 p.P149R exhibit heightened sensitivity to 
MMC, compared with cells from a related individual expressing wild type MCM8. BMN673 and 
ABT-888, in the absence of induced DNA damage, affect cells with a MT genotype similarly as it 
affects WT cells.  
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Figure 5.1 Chemical structures of cytotoxic agents.  
(A) The crosslinking agent mitomycin C, and the PARP inhibitors (B) ABT-888 and (C) BMN673. 
We compared the synthetic cytotoxicity of MMC and PARP inhibitor in cells homozygous 
for MCM8 p. P149R, heterozygous for the mutation or homozygous for wild type MCM8. We 
tested the cytotoxicity of MMC combined with PARP inhibitor in EBV-transformed lymphocytes 
homozygous for either MCM8 p.P149R or wild type MCM8. We designed these experiments to 
reveal any involvement of MCM8 in PARP-1 DNA damage recognition. While cells from patient 
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IV-1 (homozygous for MCM8 p.P149R, see Fig. 3.1) exhibit higher sensitivity to MMC than cells 
heterozygous for the mutation (patient III-2, see Fig. 3.1), or homozygous for wild type MCM8 
(patient IV-3, see Fig. 3.1), there is no observable PARP inhibitor sensitivity difference among 
cell lines.  
5.1.2 Results and Discussion 
5.1.2.1 MCM8 c.446C>G/p.P149R Cells Are Acutely Sensitive to MMC Damage 
Fibroblasts homozygous for MCM8 p.P149R (IV-6, Fig. 3.1) and fibroblasts homozygous for wild 
type MCM8 (IV-3, Fig. 3.1) were exposed to various concentrations of MMC for 6 hours and live 
cells were counted 3 days after exposure (Fig. 5.3A). A greater dose-dependent cytotoxic effect 
was observed in cells homozygous for MCM8 p.P149R. After 3 days, significantly more cells 
homozygous for MCM8 p.P149R had died than cells homozygous for wild type MCM8 (Fig. 
5.1A). This result shows that c.446C>G/p.P149R disrupts the role of MCM8 in HR to repair DNA 
damage caused by MMC, consistent with the previously observed complex chromosomal 
rearrangements in metaphase spreads after MMC exposure (Fig 3.8) (155). 
The duration-dependence of MMC exposure was tested in cells homozygous or 
heterozygous for MCM8 p.P149R (IV-6 and III-2 respectively, Fig. 3.1), as well as cells 
homozygous for wild type MCM8 (IV-3, Fig. 3.1). We determined percent viability of these three 
EBV-transformed lymphocyte cell lines 24, 48 and 72 hours after exposure to 10 nM MMC (Fig. 
5.2B). Lymphocytes homozygous for the mutation exhibit highest sensitivity to MMC of the three 
cell lines, while cells heterozygous for the mutation exhibit MMC sensitivity intermediate between 
that of the homozygous mutant and homozygous wild type.  Sensitivity increases over the 3-day 
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timecourse (Fig. 5.2B). A MMC concentration of 10 nM was selected to produce a moderate 
killing effect in lymphocytes.  
107 
Figure 5.2 MMC cytotoxicity in cells homozygous for MCM8 p.P149R. 
(A) Experimental procedure to assess cytotoxicity of MMC mutant cells, compared with cells homozygous for wild 
type MCM8; (B) Fibroblasts were exposed to various concentrations of MMC for 72 hours and the surviving fraction 
is indicated for each cell line at each concentration of MMC. (C) Cytotoxicity of 10 nM MMC was compared in EBV-
immortalized lymphocyes homozygous for MCM8 p. P149R, heterozygous for the mutation of homozygous for wild 
type MCM8. Error bars represent standard deviation of the mean comparing three independent experiments. The EC50 
was calculated based on a sigmoidal fit, determined to be 42.72 nM MMC. Cell line delineations are defined in Fig. 
3.1. 
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5.1.2.2 MCM8 c.446C>G/p.P149R Does Not Sensitize Lymphocytes to BMN673 or ABT-888 
BMN673 and ABT-888 are PARP1/2 inhibitors effective for treatment of DNA repair-deficient 
cancers (169-171). Phase II clinical trials have been completed for ABT-888 (172) while BMN673 
has not yet been as extensively characterized and is in Phase I trials (169). The sensitivity of EBV-
immortalized lymphocytes containing MCM8 p.P149R to ABT-888 and BMN673 was tested. The 
potency of the drug at 2 μM and 5 μM concentrations and effectiveness of our method was 
demonstrated in PE01 cells, a human ovarian cancer cell line known to be sensitive to PARP 
inhibition (Fig. 5.5). Lymphocytes homozygous for MCM8 p.P149R (IV-6, Fig. 3.1), 
heterozygous for the mutation (III-2, Fig. 3.1) or homozygous for wild type MCM8 (IV-3, Fig. 
3.1) were exposed to various concentrations of BMN673 in DMSO solvent, as well as DMSO 
alone as a control. Percent viability was determined 24, 48 and 72 hours following treatment. While 
PE01 cells are sensitive to BMN673 treatment, MCM8 p.P149R does not cause sensitivity to 
BMN673 (Fig. 5.3). Exposure of lymphocytes to 2 μM ABT-888 produced a similar result, 
confirming that MCM8 p.P149R does not confer sensitivity to PARP inhibitors (data not shown). 
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Figure 5.3 BMN673 cytotoxicity in EBV-immortalized lymphocytes homozygous for MCM8 p.P149R.  
(A) Experimental procedure to assess cell sensitivity to BMN673. (B) MCM8 p.P149R does not sensitize EBV-
immortalized lymphocytes to the PARP inhibitor BMN673 in cells homozygous for the mutation, (C) heterozygous 
for the mutation (D) or homozygous for wild type MCM8. Error bars represent standard deviation of the mean of three 
independent experiments. Cell line delineations are defined in Fig. 3.1. 
5.1.2.3 PARP inhibitors and MMC Have No Synthetic Lethal Effect in MCM8
c.446C>G/p.P149R 
The synergistic effect of MMC and the PARP inhibitors ABT-888 or BMN673 was tested in EBV-
immortalized lymphocytes. Cells were treated with MMC and PARP inhibitor simultaneously to 
determine whether MCM8 p.P149R is necessary for HR when the pathway is triggered by 
inhibition of PARP1/2. A MMC concentration of 10 nM was chosen as this was found to produce 
a moderate killing effect in cells heterozygous for MCM8 p.P149R (Fig. 5.2). This moderate 
concentration of MMC was combined with 2 μM BMN673, a concentration that had an observable 
killing effect in PE01 cells. There was no observable synergistic effect of MMC and BMN673 
(Fig. 5.5). A similar procedure exposing lymphocytes to MMC in combination with 2 μM ABT-
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888 produced a similar result, confirming that MCM8 p.P149R does not confer sensitivity to PARP 
inhibitors (data not shown). 
This finding suggests that while MCM8 p.P149R heightens sensitivity to DNA DSBs, this 
sensitivity does not increase when PARP is inhibited. It is possible that when PARP1/2 are 
inhibited, another factor(s) performs the role normally performed by wild type MCM8 in HR. 
Alternatively, recognition of DNA damage by PARP may be entirely separate from the action of 
MCM8 in the HR pathway. 
Figure 5.4 Synergistic cytotoxicity of MMC and BMN673 in EBV-immortalized lymphocytes homozygous for 
MCM8 p.P149R.  
(A) Experimental procedure to assess cell sensitivity to BMN673 following exposure to MMC; (B) There is no 
significant difference in the synergistic effect of MMC and BMN673 on cells homozygous for MCM8 p.P149R, 
heterozygous for the mutation or homozygous for wild type MCM8. Error bars represent standard deviation of the 
mean of three independent experiments. Cell line delineations are defined in Fig. 3.1. 
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Figure 5.5 Cytotoxicity of BMN673 in PE01 cells. 
(A) Experimental procedure to assess PE01 cell sensitivity to exposure to various concentrations of BMN673; (B) 
PE01 cells were exposed to 2 μM or 5 μM BMN673 and surviving fraction of cells was calculated each day after 
treatment, for a total of 3 days. PE01 cells are significantly sensitive to BMN673, compared with sensitivity to DMSO 
alone. Error bars represent standard deviation of the mean of three independent experiments. 
5.1.3 Conclusion 
Cells homozygous for MCM8 p.P149R are highly sensitive to DNA DSBs, supporting the role that 
has previously been proposed for MCM8 in HR repair of DSBs as well as the detrimental impact 
of this pathogenic mutant. The role of MCM8 in HR coupled with PARP1/2 inhibition is 
inconclusive, as cells homozygous for MCM8 p.P149R respond to PARP1/2 inhibition in a similar 
way to cells homozygous for wild type MCM8. Our fluorescence microscopy studies (see Section 
3) show that MCM8 p.P149R does not form foci in response to DNA damage. While it has been
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shown in Xenopus egg extract that MCM8-9 are important for recruitment of Rad51 to sites of 
DNA damage, it is possible that in a cellular context, other factors assume this recruitment role.  
Alternatively, it may be that MCM8/9 act later in the HR pathway (synapsis or 
postsynapsis) where inhibition of PARP1/2 is not synergistic with any defects in MCM8/9 because 
of temporal separation in the pathway. Many HR proteins that are synergistic with PARPi, such as 
BRCA1-2 are proposed to act early in the pathway where their detrimental effects combined with 
PARP inhibition will sensitize cells towards death. As MCM8/9 are proposed to act later in the 
pathway, recruitment of HR factors after polyadenylation of PARP1 has already begun. At this 
point, we would propose that the role of PARP1 is finished and HR repair is underway. Mutations 
in MCM8 or MCM9 would therefore have temporally separate effects from HR proteins acting 
earlier in the pathway, and cell death would result solely from the inability to resolve DNA 
crossover intermediates that have occurred showing no synergistic effect with PARP inhibition. 
5.1.4 Experimental 
5.1.4.1 Fibroblast MMC Treatment and Surviving Fraction Calculations 
Fibroblast cells were cultured in DMEM/10%FCS/penicillin-streptomycin and equal numbers 
of cells were seeded into wells of 24-well plates. Cells were exposed to MMC for 6 hours, 
washed and media was replaced. They were cultured in a humidified incubator with 5% CO2 for 
72 hours. Cells were then washed and live cells were stained with crystal violet (0.5% w/v) in 
gluteraldehyde (6% v/v). Plating efficiency (PE) was calculated for an untreated well, defined as 
PE=#colonies/#cells seeded. Surviving fraction (SF) following MMC treatment is defined as 
SF=(#colonies after treatment)/[(#cells seeded)(PE)]. This analysis was done as previously 
described (173). To determine the dose-dependent cytotoxicity of MMC, surviving fraction data 
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points were fitted to a sigmoidal expression, (0.45)/(1+10^((-EC50-x)*a)) where EC50 is the [MMC] 
corresponding to a half-maximal effect.  
5.1.4.2 EBV Lymphocyte MMC and BMN673 Treatment and Percent Viability Calculations 
EBV lymphocyte suspension cultures were grown in single wells of a 24-well plate in Dulbecco's 
Modified Eagle Medium supplemented with 4.5 g/L D-glucose, 4.5 g/L l-glutamine, 4.5 g/L 
sodium pyruvate and 10% fetal bovine serum in a humidified 5% CO2 incubator at 37°C. MMC 
and BMN673 in DMSO solutions were added to individual wells, including a DMSO-only control 
sample for each cell line. 24, 48 and 72 hours following exposure, a 10 μl sample of each was 
removed and mixed with 10 μl 0.4% trypan blue solution in PBS. Live and dead cells were counted 
using a hemacytometer for each condition and percent viability was calculated for each (Live 
Cells/Total Cells x 100).  
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6.0  FUTURE PERSPECTIVES 
Our investigation of MCM8 and MCM9 reveals their importance in homologous recombination 
(HR), which occurs both during meiotic recombination to exchange genetic material and in mitotic 
recombination as a means of repairing DNA double-strand breaks. We have identified pathogenic 
mutants of MCM8 and MCM9 in patients with premature ovarian failure and confirmed the 
previously proposed importance of these two proteins in promoting successful HR. As a means of 
advancing toward the long-term goal of defining mechanisms of DNA repair and relating this 
understanding to human disease and development of therapies, we aim to investigate the roles of 
MCM8 and MCM9 in HR. Specifically, I propose defining regions of MCM8 and MCM9 that 
participate in protein-protein interactions, and characterize the biochemical activities of the two 
proteins, including the in vivo interdependence of these functions. With a goal of enabling women 
who express pathogenic mutants of MCM8 and MCM9 to produce healthy offspring, strategies 
will be developed for generation of induced pluripotent stem cells from primary cell samples. 
6.1.1 Define MCM8 and MCM9 protein interaction sites 
As a step toward understanding the functions of MCM8 and MCM9 domains and motifs, the 
regions of MCM8 and MCM9 that engage in protein-protein interactions need to be defined.  While 
MCM8 and MCM9 form a stable nuclear complex (68), the specific regions of the two proteins 
participating in this interaction are unknown. Protein complex immunoprecipitation assays 
between truncations of the two proteins would allow for the interacting regions to be identified. 
Defining the interacting regions of the two proteins will be a significant step toward elucidating 
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the structure and orientation of the two proteins as they perform their functions. We have 
demonstrated that the C-terminal MCM9 BRCv motif is essential for DNA damage-dependent foci 
formation, and we predict that this motif directly interacts with Rad51. While colocalization at 
sites of DNA damage as well as a direct in vitro protein-protein interaction between wild type 
MCM9 and Rad51 have been previously observed (68), the region of MCM9 that interacts with 
Rad51 has yet to be defined. Protein complex immunoprecipitation assays between purified Rad51 
and truncated, mutated, or wild type MCM9 will directly define the interacting regions of the 
proteins. Testing for protein-protein interactions between MCM8-9 and other HR factors including 
BRCA1-2 would direct further investigation of the role of MCM8-9 in the HR mechanism. 
6.1.2 Examine the corecruitment of MCM8 p.P149R and MCM9 c.1732+2T>C or
p.R132* patient cell lines 
As a means of understanding the in vivo interdependence of MCM8 and MCM9 functions, I 
propose testing the effect of MCM8 mutations or depletion on the ability of MCM9 to form 
damage-dependent nuclear foci and vice versa. We predict that the C-terminal MCM9 NLS 
facilitates nuclear importation of both proteins, and one way of testing this is to transiently express 
MCM9 NLS- and GFP-tagged MCM8 in MCM9-/- cells and observe localization of MCM8. Using 
a similar approach, I would propose testing the effect of MCM8 p.P149R on the DNA damage 
response of wild type MCM9 or the effect of MCM9 c.1732+2T>C or p.R132* on wild type 
MCM8.  We have demonstrated the reduced affinity of MCM8 p.P149R for ssDNA, and the 
reduced ability of MCM8 and MCM9 mutants to form damage-induced nuclear foci. The major 
mRNA products formed from MCM9 c.1732+2T>C and p.R132* are truncated forms that lack the 
NLS and BRCv motifs, which we predict will disrupt their involvement in HR. Assessing the effect 
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of this loss of function on the ability of the interacting partner to form damage-dependent nuclear 
foci will reveal the interdependence of the cellular functions of MCM8 and MCM9.  
6.1.3 Test MCM8 and MCM9 biochemical activities 
We have demonstrated the ability of purified MCM8(1-368) to bind ssDNA, but ATP hydrolysis 
and DNA unwinding activities of MCM8, MCM9L and MCM9M have not been tested in vitro. 
These biochemical activities should be tested with purified proteins, and the affinity of MCM8 and 
MCM9 isoforms for various types of DNA substrates will also be tested. Codon-optimized 
versions of MCM8 and MCM9 expressed in E. coli could be used to facilitate purification of 
soluble protein. Coexpression/ purification of MCM8 and MCM9 should also be tried to stabilize 
the predicted complex. 
6.1.4 Continue the structural characterization of MCM8 and MCM9 
Efforts should be continued to optimize crystallization conditions for the two purified proteins, 
aiming to define a crystal structure for MCM8 and MCM9. Our initial attempts to crystalize N-
terminal domains of MCM8 resulted in small and unstable crystal forms. Possibly expressing 
longer constructs using codon optimization will result in more stable proteins amenable to 
crystallization. This will further our understanding of the molecular structure of the MCM8-9 
protein complex and will provide a structural context for its protein and DNA interactions. 
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6.1.5 Examine trans-acting MCM9 splicing regulation and cytoplasmic role of MCM9M 
Our studies do not reveal a specific function for MCM9M, and show that this protein isoform is 
localized in the cytoplasm, excluding it from any direct role in HR. These observations raise a 
question regarding the role and necessity of MCM9M. Assays to determine the interacting partners 
and biochemical activities of the MCM9 protein isoforms would reveal the specific importance of 
MCM9M in the cell, directing our future study of its function. While no function of MCM9M has 
been established, these future studies may elucidate a function of MCM9M in the cytoplasm, 
completely distinct from the function of full length MCM9L. While MCM9M and MCM9L mRNA 
transcript abundances follow a similar trend throughout a variety of cell types and at particular 
stages during the progression of the cell cycle, DNA damage differentially controls abundance of 
MCM9M and MCML transcripts. Our observation that MMC treatment of HeLa cells increases the 
abundance of MCM9L mRNA but has no effect on MCM9M mRNA suggests that the MCM9 
splicing mechanism is controlled by the presence of DNA double-strand breaks, favoring an 
increase in abundance of the fully spliced isoform when DNA damage is present. Further study of 
the splicing mechanism under conditions of DNA damage is necessary to understand this 
differential splicing of the MCM9 gene. 
6.1.6 Create genetically modified embryos for women afflicted by POF 
While hormone replacement therapy is currently used for symptom management in patients 
afflicted with POF and homozygous for MCM8 p. P149R or MCM9 c.1732+2T>C or p.R132*, 
no therapy has been implemented to allow the affected individuals to produce viable offspring. By 
combining recently available techniques, there is a possibility for these women to have viable 
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offspring without passing on the pathogenic MCM8 or MCM9 mutations. For example, the MCM8 
or MCM9 mutation could be corrected by newly developed CRISPR technologies in a cell line 
isolated from the patient, and used to generate induced pluripotent stem cells. This technique has 
already been implemented, as induced pluripotent stem cells have been generated from human 
fibroblasts (174). From these stem cells, an oocyte may be developed, using a similar approach to 
what has been successfully developed in mice (175). The generated oocyte may be fertilized in 
vitro, producing embroys whose genome will contain wild type MCM8 or MCM9 instead of the 
pathogenic mutant. 
6.1.7 Investigate further coincidence of POF and recombination defects 
The expected outcome of these efforts is a further understanding of the mechanism of HR, as well 
as the deleterious outcomes of defects in this mechanism. While there is a known relationship 
between premature ovarian failure and defects in the HR involvement of MCM8 and MCM9, we 
expect that a greater understanding of HR will have an impact beyond understanding this disease. 
Meiotic recombination is a fundamental process in all sexually reproducing organisms, and defects 
in this process have profound effects on the cell, including aneuploidy and mis-segregation of 
chromosomes. Defects in HR also lead to an inability to repair double-strand breaks, which may 
lead to unregulated cell division and cancerous tumor development. Due to the essential and 
foundational nature of HR, we expect that a further understanding of its mechanism will have a 
broad positive impact on the field of molecular biology.  
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